Research Advances in How the cGAS-STING Pathway Controls the Cellular Inflammatory Response

Dongshan Wan¹,², Wei Jiang² and Junwei Hao¹*

¹ Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China, ² Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China

Double-stranded DNA (dsDNA) sensor cyclic-GMP-AMP synthase (cGAS) along with the downstream stimulator of interferon genes (STING) acting as essential immune-surveillance mediators have become hot topics of research. The intrinsic function of the cGAS-STING pathway facilitates type-I interferon (IFN) inflammatory signaling responses and other cellular processes such as autophagy, cell survival, senescence. cGAS-STING pathway interplays with other innate immune pathways, by which it participates in regulating infection, inflammatory disease, and cancer. The therapeutic approaches targeting this pathway show promise for future translation into clinical applications. Here, we present a review of the important previous works and recent advances regarding the cGAS-STING pathway, and provide a comprehensive understanding of the modulatory pattern of the cGAS-STING pathway under multifarious pathologic states.

Keywords: inflammation, cGAS, STING, cGAMP, type I interferonopathies

INTRODUCTION

Pattern-recognition receptors (PRRs) serve as innate cellular sensors of danger signals, such as pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs), and yield cellular-stress response. DNA molecules are vital genetic components within cells, which are compartmentalized restrictively into specific regions. The occasionally misplaced DNA is degraded rapidly by scavenger cells and extracellular or intracellular ribonucleases. Aberrant accumulation of DNA is relevant to tissue damage (1).

In 2008, several research teams discovered a new protein on the endoplasmic reticulum (ER) which can be activated by immune-stimulatory DNA (ISD) and initiate type-I interferon (IFN) responses, which was named "stimulator of interferon genes" (STING, also known as MITA, ERIS) (2–4). STING does not bind to DNA directly, and bacteria-derived cyclic di-guanylate monophosphate (c-dGMP) or cyclic di-adenosine monophosphate (c-dAMP) were confirmed to be ligands for STING (5, 6). Subsequently, it was found that some DNA sensors can facilitate STING activation, such as interferon gamma inducible protein 16 (IFI16) (7). However, STING activation could not be fully explained by the upstream factors/ligands that had been found. It was postulated that an unknown upstream regulator might be responsible for STING activation.

In 2013, Wu and Sun found that cyclic guanosine monophosphate-adenosine monophosphate (cGMP) was a novel secondary messenger serving as a ligand of STING (8). Beside it, they purified a new protein named "cyclic-GMP-AMP synthase" (cGAS) that had cytosolic DNA-sensing ability and can synthesize cGAMP (8). Also, they found that the cGAS-cGAMP-STING pathway was indispensable for host anti-viral immunity (9). Their work filled in the gaps missing from upstream of STING.

Stimulator of interferon genes or cyclic-GMP-AMP synthase is expressed widely in a broad spectrum of cells including immune, non-immune, cancer cells (10). Mounting
evidence has demonstrated that the cGAS-STING pathway is important for mediating cellular immune sensing, and shows particular responses pattern to the ISD distinguished from other nucleotide-sensing pathways. It is also regulated delicately by several molecules or feedback loops to maintain cellular homeostasis. Nevertheless, cGAS-cGAMP-STING pathway itself has distinctive or even opposing effects under different conditions.

In this review, we cover the roles of cGAS-STING pathway in cellular type-I IFN immune response, and several cellular processes including autophagy, survival and senescence. We also summarize the literature on intrinsic cellular mechanisms modulating cGAS-STING pathway as well as its cross-regulations with other DNA-sensing pathways. Moreover, the inflammation-modulation capacities of this pathway in infectious disease, inflammation and cancers have been elucidated too, and a pervasive pattern of this pathway has been described, which could provide a plausible explanation of the contradictory findings of studies. Finally, current or prospective therapeutic strategies targeting the pathway, and issues that need to be addressed in the future, are discussed.

**cGAS RECOGNIZES CYTOSOLIC DNA AND PRODUCES cGAMP**

Cyclic-GMP-AMP synthase belongs to the structurally conserved cGAS/DncV-like nucleotidyltransferase (CD-Ntases) superfamily. The latter is expressed universally in prokaryotes and eukaryotes, and can use purines or pyrimidines selectively as substrates for the production of linear or cyclic di- or even tri-nucleotide compounds, which act as secondary intracellular messengers (11).

Cyclic-GMP-AMP synthase is distributed mainly in the cytosol (also nucleus in some specific conditions) (8). Generally speaking, cGAS is activated upon the recognition of B-type double-stranded DNA (dsDNA) without sequence-specificity but not A-type dsDNA or RNA (12, 13). Hybrid DNA:RNA or stem-like single-stranded DNA (ssDNA) are also low-affinity ligands for cGAS (14, 15). After binding with ligands, cGAS undergoes an allosteric structural change, and subsequently catalyzes its substrates guanosine triphosphate (GTP) and adenosine triphosphate (ATP) to produce a mixed phosphodiester-linked cyclic dinucleotide: G(2′-5′)pA(3′-5′)p cGAMP (abbreviated as 2′,3′-cGAMP or cGAMP) (16). cGAS also catalyze the synthesis of linear dinucleotides such as AMP-2′-ATP, GMP-2′-GTP, and AMP-2′-GTP as intermediate products (17).

There are two major dsDNA-binding sites on opposite sides of the catalytic pocket: A and B site. Site A is the primary contact surface for dsDNA, whereas site B is complementary, binding another dsDNA. It allows for cGAS to the formation of a 2:2 cGAS:dsDNA complex structure directed into two orientations with dsDNA at least 20 bp (18–20) (Figure 1A). Increased numbers of back-to-back dimers of cGAS hold the two dsDNA molecules together and permit successive recruitment of cGAS which, consequently, forms a 2n:2 cGAS:dsDNA higher-ordered “ladder-like” oligomerization, with cGAS arrayed “head to head/tail to tail” (19, 21). The DNA-binding protein HU, mitochondrial transcription factor A (TFAM), or bacterial high mobility group box 1 protein (HMGB1) can bend the dsDNA into a U-shaped structure and, thus, facilitate binding of cGAS dimers to the same strand as it travels in opposite directions (21) (Figure 1B). Human cGAS, unlike mouse cGAS, is prone to formation of this ladder-like network with long dsDNA, because of the human-specific residues K187 and L195. These two dsDNA-interacting residues of site A loosen the interaction of dsDNA with cGAS, leading to dsDNA curving and allowing more convenient binding for the next adjacent cGAS (20, 21) (Figure 1C). Finally, accumulated cGAS-dsDNA complexes can go through a liquid-phase separation and condense into gel-like droplets as a reaction unit (Figure 1D). This conformation requires a sufficiently long dsDNA strand to form multivalent interaction positions, also requires the function of the N-terminal tail of cGAS and a recently discovered dsDNA-binding site in the catalytic domain of cGAS (site C) (22, 23). Meanwhile, the N-terminal tail of cGAS mediates cGAS localization onto the membrane by binding to phosphatidylinositol 4,5-bisphosphate (PI (4, 5) P2) and prevents liberation of cGAS and oligomerization, but can release cGAS during cell stress (24). The structure of cGAS determines long strand dsDNA (>500–1,000 bp) could potentially stimulate the enzyme activity and cGAMP production of cGAS (25). The ability of human cGAS to discriminate long dsDNA strands from shorter dsDNA may contribute to the specific sensing and recognition of the “danger DNA” of pathogens, necrotic cells or cancer cells rather than irrelevant shorter dsDNA, thereby enhancing the immunity against them specifically.

**ACTIVATION OF THE cGAS-STING PATHWAY**

Double-stranded DNA is restricted into the nucleus or mitochondria and is rarely present in the cytoplasm. Extrinsic dsDNA from pathogens such as viruses, bacteria, transcellular vesicles or rupture of dying cells can be internalized into the cytosol in several diverse ways (26–28). These extrinsic dsDNA sources are engulfed by endosome through phagocytosis and digested immediately by DNaseII when fusing with lysosomes (29, 30). However, some escaping mechanisms under certain conditions could help protect them from being degraded. For example, antimicrobial peptide LL37 could efficiently transports self-DNA from endosome into cytosol of monocytes (28). Cell oxidative stress can lead to phagosomal acidification delay and probably release endosome context including dsDNA owing to increased membrane permeability (27, 31).

The intrinsic self-dsDNA can also be segregated inaccurately and released into the cytosol (32, 33). For example, genomic DNA (gDNA) injury as a result of genotoxic stress and DNA self-instability or replication errors leads to double-strand breaks (DSBs) and can be repaired by several ways (34). Impaired mediators of DNA-damage repair response mediators, such as ataxia telangiectasia mutated (ATM)-RAD3, poly ADP-ribose polymerase (PARP) and breast cancer1/2 (BRCA1/2)
cGAS can recognize cytosolic DNA and produce cGAMP. (A) There are two DNA-binding sites on opposite sides of the catalytic pocket (site A, B) and a proposed DNA-binding site at the catalytic domain of cyclic-GMP-AMP synthesis (cGAS) (site C). (B) Multiple cGAS molecules can bind two double-stranded DNAs (dsDNA) to form a 2n:2 cGAS:dsDNA higher-ordered “ladder-like” oligomerization. Mitochondrial transcription factor A (TFAM) can bend the dsDNA into a U-shaped structure and promote polymerization. (C) cGAS can recognize B-type dsDNA. In humans, the cGAS DNA-interfacing residue of site A loosens the interaction of dsDNA to curve dsDNA away for more convenient binding with next adjacent cGAS. cGAS can catalyze GTP and ATP to synthesize cyclic guanosine monophosphate-adenosine monophosphate (cGAMP). The N-terminal tail binds to the cell membrane, associating with phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2]. (D) Accumulation of cGAS-DNA complex goes through a liquid-phase separation and condenses into gel-like droplets.

are associated with persisting DSBs and accumulation of cytosolic DNA (35–37). Extra-nuclear micronuclei formation during mitosis is a source of cytosolic dsDNA caused by DSBs (32, 38). Followed by homologous recombination repair of collapsed replication forks, DNA cleavage by methyl methanesulphonate (MMS) and ultraviolet-sensitive 81 (MUS81) also lead to cytosolic dsDNA presenting (39). Furthermore, manually Cre/loxP recombination technology can induce dsDNA damage during DNA cleavage, which results in the accumulation of cytoplasmic dsDNA (40). In normal cellular mitotic processes, chromosomal DNA can be exposed to the cytoplasm, while it is hard to bind and trigger cGAS (41).

In addition, mitochondrial DNA (mtDNA) is also a considerable ligand of cGAS and can be released into the cytosol under mitochondrial stress or dysfunction of proteins which participates in maintaining mitochondrial operations (33, 42, 43) (Figure 2A).

Cells have several types of nucleases to restrict cytosolic DNA to avoid cGAS activation. For example, three-prime repair exonuclease 1 (TREX1 also known as DNaseIII) is a cytosolic DNA exonuclease which removes unprotected dsDNA from the cytosol (44). RNaseH2 locates to the nucleus and specifically degrades the RNA in RNA:DNA hybrids participating in DNA replication (45). DNaseII is a lysosomal DNase which degrades undigested DNA in endosomes or autophagosomes to prevent their entry into the cytoplasm (30). SAM domain and HD domain-containing protein 1 (SAMHD1) is characterized as a dNTPase and restricts reverse transcription of the RNA virus (46, 47). SAMHD1 can also stimulate the exonuclease (but not the endonuclease) activity of MRE11 to degrade nascent
ssDNA, and start DNA-repair responses at stalled replication forks (48). Depletion of SAMHD1 leads to the cleaving of nascent ssDNA by the activity of MRE11 endonuclease and cytosolic translocation of gDNA (48). Deficiency of any of these nucleases can lead to accumulation of self-DNA in the cytoplasm, thereby activating the cGAS-STING pathway against DNA molecules (30) (Figure 2A).

cGAMP CAN TRANSFER BETWEEN CELLS AND ACTIVATE STING

The production of asymmetrically linked 2′,3′-cGAMP catalyzed by cGAS has the highest affinity for STING to promotes STING dimerization (49, 50). cGAMP as a second messenger can be also transferred among cells in several ways to pass danger signaling of...
cytosolic DNA. Intercellular gap junction consists of two docking hexamer channels formed by different connexins, which allows many small molecules, including cGAMP, to pass bi-directionally through cells. And intercellular transfer of cGAMP through gap junction is largely dependent on connexin 43 (51–53). Additionally, cGAMP can be packaged into virosomes and pre-notify newly infected cells (54, 55). Cell fusion is a distinct manner for intracellular transmission of the human immunodeficiency virus (HIV); cGAMP also enter membrane-fused bystander cells in this way (56). Extracellular vesicles such as exosomes can contain cGAMP along with viral DNA, host gDNA or mtDNA, and mediate cells communication (57, 58). There were no evidences that cGAMP could be pumped out to extracellular space by a channel/transporter. However, it was found that SLC19A1 can transmit cyclic dinucleotides (CDNs) into cell plasma (59, 60). Notably, ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP-1) can degrade extracellular cGAMP (61) (Figure 2B). Besides triggering STING, these exogenous cGAMP can directly bind to cGAS and prompt its activation as well (62).

After binding to cGAMP, the “lid” region of the STING dimer undergoes a conformational change that converts STING from an inactive “open” formation to an active “closed” formation. Following that, the STING dimer translocates from the ER to perinuclear ER-Golgi intermediate compartment (ERGIC) vesicles, finally arriving at the Golgi to form punctuate structures with downstream molecules (2, 63). ER-retention of STING caused by mutations results in reduced IFN signaling (64, 65). The translocon-associated protein β (TRAPβ) recruited by inactive rhomboid protein 2 (iRhom2) initially forms the TRAP translocon complex that mediates STING exit from the ER (2, 66). They both assist cytoplasmic coat protein complex-II (COPII) to drive ER-vesicle formation and carry the STING complex to the Golgi (67, 68).

 Trafficking STING can bind directly to and be phosphorylated by TANK binding kinase 1 (TBK1) dimer or IkB kinase (IKK) complex (3, 69, 70). The C-terminal tail (CTT) of STING is a linear unfolded segment, which determines the optimization of combination specificity. STING CTT in mammals tends to be phosphorylated, while TBK1 phosporylate each other (72, 73). Hence, STING and TBK1 can aggregate on the Golgi to form the STING signalosome. Clustering STING undergoes palmitoylation and full activation (74). It is also possible for STING-IKK to cluster and form the STING signalosome in this manner. The STING-TBK1/IKK signalosome produces a scaffold to phosphorylate interferon regulatory factor 3 (IRF3) or inhibitor of NF-κB (IkBα). Activated IRF3 undergo dimerization (70). The activation of IkBα leads to its polyubiquitination and degradation by the proteosome, thereby eliminating its inhibition of NF-κB. There is also evidence suggesting that NF-κB activation might not require STING trafficking from the ER (75). Then, the dimerized IRF3 or activated NF-κB p50/p65 (p65 is also known as RelA) complex are translocated into the nucleus as transcription factors and bind to the promoter of type-I IFN to aid the transcription of type-I IFN (2, 3, 70). Meanwhile, activation of NF-κB p52/RelB can prevent recruitment of p65 and inhibit the p50/p65 signal (76) (Figure 2C).

**STING DOWNSTREAM SIGNALING PROMOTES IFNα/β EXPRESSION AND AUTOPHAGY**

Expressed type-I IFN can propagate among cells in paracrine or autocrine manners. The binding of IFNα/β with its receptor triggers janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways, then induce transcription of type-I IFN-stimulated genes (ISGs), which have IFN-sensitive response elements (ISREs) in their 5′-untranslated regions (UTRs) (77). IRF3 can also bind partially to several ISREs alone (78). Herein, the expression of some ISGs including interferon-inhibited protein with tetratricopeptide repeats (IFIT) and pro-inflammatory cytokines such as tumor necrosis factor α (TNFα), interleukin (IL)-6, C-X-C motif chemokine ligand 10 (CXCL10) and C-C motif chemokine ligand 5 (CCL5) is increased remarkably by the cGAS-STING pathway (79). Furthermore, cGAS and STING are both ISGs, suggesting a positive feedback loop in spreading of the IFN signal (80, 81).

Stimulator of interferon genes activation on the ER also triggers an ER stress response with an “unfolded protein response” (UPR) motif on the C-terminus of STING, which leads to and ER stress-mediated autophagy (82, 83). STING-TBK1 activation and ER stress also induce mechanistic target of rapamycin complex 1 (mTORC1) dysfunction (84). ER stress or reduced mTORC1 signaling activates Unc-51-likeautophagy activating kinase (ULK1) complex and the Beclin-1-class III phosphatidinositol 3-kinase 3-kine (PI3KC3 also known as VPS34) complex, which promotes initiation of the classical autophagy path (85). cGAS can also interact directly with the autophagy protein beclin-1-PI3KC3 complex and trigger autophagy (86). Furthermore, cGAS-dsDNA polymer can form a liquid-phase condensate as mentioned above, which could theoretically be an initiator of autophagy (87). After autophagy initiation, autophagy-related protein 9 (ATG9) undertakes the genesis of the autophagosome along with light chain3 (LC3) undergoing lipidation, thereby resulting in elongation of the autophagosome (88). LC3 can also be recruited directly by ERGIC-loading STING and bypass the classical autophagy pathway (68, 89).

cGAS-STING-mediated autophagy can spread to the whole cell and help the elimination of intracellular microorganisms, subcellular organelles or misfolded proteins, as well as the ER itself that loads the STING signalosome (90–92) (Figure 2D). cGAS-STING-mediated autophagy is also indispensable for removing cytosolic DNA and inflammatory signaling factors to restrict the inflammatory response raised by the pathway itself (93). Excessive signaling of the autophagy cascade can lead to irreversible apoptosis termed “autophagic cell death” (94). Consequently, oligomerized cGAS or activated cGAS-STING mediated autophagy can spread to the whole cell and help the elimination of intracellular microorganisms, subcellular organelles or misfolded proteins, as well as the ER itself that loads the STING signalosome (90–92) (Figure 2D). cGAS-STING-mediated autophagy is also indispensable for removing cytosolic DNA and inflammatory signaling factors to restrict the inflammatory response raised by the pathway itself (93). Excessive signaling of the autophagy cascade can lead to irreversible apoptosis termed “autophagic cell death” (94). Consequently, oligomerized cGAS or activated cGAS-STING mediated autophagy can spread to the whole cell and help the elimination of intracellular microorganisms, subcellular organelles or misfolded proteins, as well as the ER itself that loads the STING signalosome (90–92) (Figure 2D). cGAS-STING-mediated autophagy is also indispensable for removing cytosolic DNA and inflammatory signaling factors to restrict the inflammatory response raised by the pathway itself (93). Excessive signaling of the autophagy cascade can lead to irreversible apoptosis termed “autophagic cell death” (94). Consequently, oligomerized cGAS or activated cGAS-STING mediated autophagy can spread to the whole cell and help the elimination of intracellular microorganisms, subcellular organelles or misfolded proteins, as well as the ER itself that loads the STING signalosome (90–92) (Figure 2D). cGAS-STING-mediated autophagy is also indispensable for removing cytosolic DNA and inflammatory signaling factors to restrict the inflammatory response raised by the pathway itself (93). Excessive signaling of the autophagy cascade can lead to irreversible apoptosis termed “autophagic cell death” (94). Consequently, oligomerized cGAS or activated cGAS-STING mediated autophagy can spread to the whole cell and help the elimination of intracellular microorganisms, subcellular organelles or misfolded proteins, as well as the ER itself that loads the STING signalosome (90–92) (Figure 2D). cGAS-STING-mediated autophagy is also indispensable for removing cytosolic DNA and inflammatory signaling factors to restrict the inflammatory response raised by the pathway itself (93). Excessive signaling of the autophagy cascade can lead to irreversible apoptosis termed “autophagic cell death” (94). Consequently, oligomerized cGAS or
STING undergoes ubiquitination and is packaged into autophagosomes with the help of p62, to be terminally sorted into lysosomes (79, 83, 95, 96). cGAS or STING is digested immediately in the autophagolysosome after transient activation of downstream signaling (68, 79, 83, 89). Autophagy functions as a negative feedback loop which ensures transient cGAS-STING signaling and avoids consistent over-reaction of the pathway. Thus, impairment of autophagy may give rise to destructive inflammatory diseases (31).

REGULATION OF THE cGAS-STING PATHWAY

We cataloged factors in the literature that could potentially up- or down-regulate expression of cGAS/cGAMP/STING in pre-translational or post-translational stages (Tables 1, 2). The regulatory mechanisms of TBK1, IRF, and NF-κB in signaling pathways associated with expression of type-I IFN are outside the scope of this review.

CROSS-REGULATION OF THE cGAS-STING PATHWAY WITH OTHER DNA-SENSING PATHWAYS

PYHIN family member absent in melanoma 2 (AIM2) is a cytoplasmic dsDNA sensor. It can recruit apoptosis-associated speck-like protein containing a CARD (ASC) by its PYHIN domain and form the AIM2 inflammasome. The inflammasome activates caspase-1, which activates IL-1 and trigger pyroptosis (97). The AIM2 pathway could counteract the cGAS-STING pathway (98). First, cGAS is a target for caspase-1 cleavage (99). Second, gasdermin D activated by caspase-1 can lead to potassium ion (K+) efflux which inhibits cGAS (100). Conversely, the cGAS-STING pathway can trigger the AIM2 inflammasome or NLR family pyrin domain containing 3 (NLRP3) by several

### TABLE 1 | Factors promoting cGAS-STING pathway.

| Functions               | Factors       | Targets       | Mechanisms                                      | References |
|-------------------------|---------------|---------------|-------------------------------------------------|------------|
| E3 ubiquitination       | TRIM56        | cGAS          | Monoubiquitination at K335                       | (277)      |
|                         |               | STING         | K63-linked polyubiquitination at K150            | (278)      |
|                         | RNF185        | cGAS          | K27-linked polyubiquitination at K173/384        | (279)      |
|                         | RNF26         | STING         | K11-linked polyubiquitination at K150            | (280)      |
|                         | AMFR INSIG1   | STING         | K27-linked polyubiquitination at K137/150/224/236| (281)      |
|                         | MUL1          | STING         | K63-linked ubiquitination of K224                | (75)       |
| Deubiquitination        | USP14         | cGAS          | Cleaving K48-linked polyubiquitin chain at K414  | (282)      |
|                         | USP21         | STING         | Cleaving K27/63-linked polyubiquitin chain       | (283)      |
|                         | USP20         | STING         | Cleaving K27/63-linked polyubiquitin chain       | (284)      |
|                         | CYLD          | STING         | Cleaving K48-linked polyubiquitination           | (285)      |
|                         | EIF3SS5       | STING         | Cleaving K48-linked polyubiquitination           | (66)       |
| E3 SUMOylation          | TRIM38        | cGAS          | Sumoylating at K231/479 to prevent polyubiquitination | (286) |
|                         |               | STING         | Sumoylating of STING at K338 to prevent polyubiquitination | (286) |
| De-SUMOylation          | SENP7         | cGAS          | Cleaving SUMO on the K335/372/382                | (287)      |
| Directly interacting    | G3BP1         | cGAS          | Supporting formation of large cGAS complexes     | (288)      |
|                         | zinc ion      | cGAS          | Promoting cGAS liquid phase condensation         | (22)       |
|                         | ZOCHC3        | cGAS          | Enhancing the binding of cGAS to dsDNA           | (289)      |
|                         | Manganese ion | cGAS          | Enhancing the binding of cGAS to dsDNA           | (290)      |
|                         | STING         |               | Enhancing cGAMP-STING binding affinity           |            |
|                         | TMEM203       | STING         | Promoting activation                             | (291)      |
|                         | ZDHHC1        | STING         | Promoting dimerization                           | (292)      |
|                         | TMED2 or TMED10| STING        | Promoting recruitment of STING into the COPII Complex for trafficking | (67)      |
|                         | iFT3          | STING- TBK1   | Promoting STING-TBK1 binding                     | (293)      |
|                         | S6K1          | STING- TBK1   | Forming of a tripartite S6K1-STING-TBK1         | (294)      |
|                         | GSK3b         | STING-TBK1    | Promoting TBK1 autophosphorylation at Ser172 and promoting its binding to STING | (295, 296) |
| Processing body-associated protein | LSm14A | STING         | Processing STING nuclear mRNA precursor and maintaining mRNA level | (297) |

TRIM, tripartite motif-containing; UBXNs, ubiquitin regulatory X domain-containing proteins; RNF, RING finger domain; AMFR, autocrine motility factor receptor; INSIG1, insulin-induced gene 1; MUL1, mitochondrial E3 ubiquitin protein ligase 1; USP2, ubiquitin-specific protease; CYLD, cylindromatosis; EIF3SS5, eukaryotic translation initiation factor 3SS; Rhom2, inactive rhomboid protein 2; SUMO, small Ubiquitin-like Modifier; SENP7, sentrin/SUMO-specific protease 7; G3BP1, activating protein SH3 domain-binding protein 1; ZOCHC3, COCHC-type zinc-finger protein 3; TMEM, transmembrane protein; TMED, transmembrane protein p24 trafficking protein 1; TRAP, translocon-associated protein; iFT3, interferon-induced protein with tetraactopeptide repeats 3; S6K1, ribosomal protein S6 kinase 1; mTOR, mechanistic target of rapamycin; GSK3b, glycogen synthase kinase 3b; CREB, c-AMP-response element binding protein.
**TABLE 2 | Factors inhibiting cGAS-STING pathway.**

| Functions          | Factors | Targets | Mechanisms | References |
|--------------------|---------|---------|------------|------------|
| E3 ubiquitination  | TRIM29  | STING   | K48-linked ubiquitination at K370 | (298)      |
|                    | TRIM30a | STING   | K48-linked ubiquitination at K275 | (299)      |
|                    | RNF5    | STING   | K48-linked ubiquitination at K150 | (300)      |
| Deubiquitinating   | USP13   | STING   | K27-linked deubiquitination at ? | (301)      |
| Desumoylation      | Senp2   | cGAS    | Desumoylating at K231/479 allowing K48-linked ubiquitination | (286)      |
|                    |         | STING   | Desumoylating at K338 allowing K48-linked ubiquitination | (244)      |
| Directly interacting | Cia-cGAS | cGAS    | A circular RNA harboring a stronger affinity than dsDNA | (139)      |
|                    | OASL    | cGAS    | Ubiquitin-like domain inhibiting cGAS enzymatic activation | (302, 303) |
|                    | AKT1    | cGAS    | Phosphorylating the S291/S305 of the enzymatic domain | (245)      |
|                    | STING   | STING   | Retaining STING in the ER membrane without activation | (305)      |
|                    | Nitro-fatty acids | STING  | Nitro-alkylation inhibiting palmitoylation | (306)      |
|                    | NLRC3   | STING/STING | Blocking STING-TBK1 interaction | (307)      |
|                    | PPM1A   | STING/STING | Dephosphorylating | (308)      |
|                    | PTPN1/2 | STING   | Dephosphorylating at Y245 | (309)      |
|                    | NLRX1   | STING/STING | Blocking STING-TBK1 interaction | (310, 311) |
|                    | SOX2    | STING   | Promoting autophagy-dependent degradation | (312)      |
| MicroRNA            | miRNA25/90 | cGAS | Inhibiting expression of NCOA3 which promotes transcription | (313)      |
| transcription factor | Nrf2    | STING   | Decreasing mRNA stability | (314)      |
| Histone H3K4        | KDM5    | STING   | Suppressing the expression | (315)      |
| lysine demethylase  | ENPP1   | cGAMP   | Hydrolyzing cGAMP | (61)       |

Senp2, sentrin/SUMO-specific protease 7; TRIM, tripartite motif-containing; RNF5, RING finger domain; USP, ubiquitin-specific protease; OASL, 2′-5′-oligoadenylate synthase; mTORC2, mechanistic target of rapamycin complex 2; DDX58, DExD/H-box helicase 58; STIM1, stromal interaction molecule 1; NLRC3, NOD-like receptor family CARD domain containing; mTORC3, NOD-like receptor family CARD domain containing; PPM1A, protein phosphatase 1A; PTPN, protein tyrosine phosphatases non-receptor type; NLRC1, NLR family member X1; SOX2, SRY-box 2; Nrf2, nuclear factor (erythroid-derived 2)-like 2; KDM5, lysine-specific demethylase 5; ENPP1, ectonucleotide pyrophosphatase/phosphodiesterase family member 1; NCOA 3, nuclear receptor co-activator 3; TLR, Toll-like receptors.

means, and the process lags behind canonical IFN signaling (96, 101). In this way, the inhibitory nucleic-acid sensor NLR family CARD domain containing 3 (NLRC3) can counteract STING by binding and occupying it, but viral DNA as a possible NLRC3 ligand can reverse its occupation of STING (102) (Figure 3A).

Another PYHIN family member, IFI16, is a DNA sensor located in the nucleus. IFI16 can bind to viral DNA sequences or damaged chromatin DNA and be translocated to the cytoplasm to recruit STING cooperatively with TNF receptor associated factor 6 (TRAF6) and p53 (103, 104). Several studies have shown that IFI16 (which can stimulate the phosphorylation and recruitment of STING and TBK1) is required for the full response of STING (105, 106) (Figure 3B). Conversely, cGAS can partially enter the nucleus and interact with IFI16 to promote its stability (107). Therefore, it is inferred that during viral infection, IFI16 can facilitate recognition of decapsidated viral DNA in the nucleus, while cGAS in the cytoplasm engages with viral gene transcription products (104, 108). However, STING signaling can trigger IFI16 degradation by tripartite motif-containing 21 (TRIM21) ubiquitination (109).

TLR is also an important PRR for multiple PAMPs (110). TIR domain-containing adaptor-inducing IFNβ (TRIF) is downstream of several subtypes of TLRs (including TLR3). TRIF may be responsible for interacting with STING and helping the dimerization of STING (111). During viral infection, the TLR9-myeloid differentiation primary response 88 (MYd88)-IRF3/7 pathway is necessary for mouse monocytes recruitment to lymph nodes, whereas the STING pathway is necessary for local production of type-I IFN (112). However, STING signaling can induce suppressor of cytokine signaling1 (SOCS1) expression, which can negatively regulate MyD88 activity (113) (Figure 3C).

cGAS-STING PATHWAY IN CELL SURVIVAL

Oxidized mtDNA can be released into the cytoplasm during cell stress elicited by hypoxia, viral infection and mitochondrial damage, etc.; oxidized mtDNA is resistant to degradation by the cytosolic nuclease TREX1 (114). In addition, mtDNA accompanied with TFAM (a mtDNA-binding protein that can bend mtDNA) is also a reasonable target for recognition by cGAS (21, 33). However, during regulated cell death (as represented by apoptosis), it undergoes mtDNA release but has certain mechanisms to ensure a minimal cGAS-STING-mediated immune response. Mitochondrial outer membrane permeabilization (MOMP) activation, which is executed by BCL-2-associated X protein (BAK) and BCL-2 antagonist or killer (BAK), is a highly controlled conserved process in regulated cell...
FIGURE 3 | Interaction of the cGAS-STING pathway with other DNA-sensing pathways and its role in cell survival. (A) Absent in melanoma2 (AIM2) pathway and pyroptosis and necroptosis. AIM2 can be triggered by cGAMP and form an inflammasome, consequently triggering interleukin (IL)-1 production and pyroptosis. Stimulator of interferon genes (STING) trafficking to the lysosome ruptures the lysosome membrane, resulting in K+ efflux and activation of the NLRP3 inflammasome, leading to pyroptosis. Cyclic-GMP-AMP synthase (cGAS) and interferon regulatory factor 3 (IRF3) can be a target for caspase-1 cleaving. Gasdermin D can lead to K+ efflux and inhibition of cGAS. (B) Interferon gamma inducible protein 16 (IFI16). IFI16 can be transported to the cytoplasm to help to recruit STING and TANK binding kinase 1 (TBK1). IFI16 as a PYHIN family protein may form the inflammasome only in theory. (C) Toll-like receptor (TLR) pathway. TIR domain-containing adaptor-inducing IFNβ (TRIF) may be responsible for helping the dimerization of STING. STING signaling can induce suppressor of cytokine signaling 1 (SOCS1) expression, which negatively regulates MyD88 activity. (D) Apoptosis. Mitochondrial outer membrane permeabilization (MOMP) formed by BAX/BAK induced by mitochondrial stress can release oxidized mitochondrial DNA (mtDNA) and cytochrome c into the cytosol. Oxidized mtDNA is a suitable ligand for cGAS recognition and is resistant to DNaseIII (TREX1) degradation. Cytochrome c binds to apoptotic protease-activating factor 1 (APAF1) and initiates the formation of an apoptosome cooperatively with caspase-9 to activate caspase-3, which can induce apoptosis. Caspase-3 can cleave cGAS.

diagram death. BAK and BAX activated by apoptosis signals cooperatively form a pore-like conformation on the mitochondrial outer membrane, leading to a permeability change of outer and also inner membranes (115, 116). Consequently, the mitochondrial matrix, including cytochrome C and oxidized mtDNA-TFAM, is released into the cytoplasm (115, 117). Cytochrome C binds to apoptotic protease-activating factor 1 (APAF1) and initiates the formation of the apoptosome cooperatively with caspase-9, which further triggers the intrinsic apoptosis program (117). In vivo and in vitro studies have shown that an absence of caspase-9 is associated with greater release of type-I IFN (43, 117). This occurs because caspase-9 and its downstream caspase-3 can cleave cGAS and IRF3 to restrain deleterious inflammation (118) (Figure 3D).

The cGAS-STING pathway can also initiate programmed cell death. Activation of STING enhances phosphorylation and activation of receptor interacting serine/threonine kinase 3 (RIP3) and mixed lineage kinase domain-like pseudokinase (MLKL). Proapoptotic BCL2 binding component 3 (PUMA), a member of BH3-only family, is subsequently activated in
Moreover, stimulating STING-dependent type-I IFN and TNFα ultimately resulting in pyroptosis (96, 101) (Figure 3D). LCD further triggers K+ efflux and NLRP3 activation, ultimately resulting in pyroptosis (96, 101) (Figure 3D). Moreover, stimulating STING-dependent type-I IFN and TNFα signals simultaneously can lead to necroptosis of tumor cells (122, 123).

**cGAS-STING PATHWAY IN CELL SENESCENCE**

Cell senescence is recognized as a permanent arrest of the cell cycle, and is common in aging, immunity, ontogenesis and infectious defense (124). It lacks a specific biomarker but can be identified by the expression of several anti-proliferative molecules (representatively Rb-p16 and p53-p21 pathway) (125). During senescence, changes in the nuclear structure and loss of the nuclear lamina protein disrupt the integrity of the nuclear envelope, leading ultimately to DNA damage and cytoplasmic chromatin fragments (126). Cellular senescence can be accelerated by accumulation of cytoplasmic chromatin in turn (127). These senescent cells produce the senescence-associated secretory phenotype (SASP), which shapes an inflammatory microenvironment (128). The cGAS-STING pathway has been reported to be involved in the recognition of cytoplasmic chromatin fragments from senescence-related DNA damage, and mediate the expression of SASP genes (129–132). Along with these actions, the expression of TREX1 and DNaseI is inhibited by DNA damage through the inhibition of E2F/DP (a potential transcription factor of TREX1 and DNaseI) (130).

For hematopoietic stem cells (HSCs), DNA damage can promote excessive secretion of type-I IFN in the HSC niche and activate p53 pathway, both of which can lead to long-term senescence and exhaustion of HSCs (133, 134). HSCs expressing a circular RNA named "cia-cGAS" in the nucleus, however, are protected from this exhaustion as a result of cia-cGAS having stronger affinity than that of self-DNA, which prevents it from being sensed (135). It implied a novel target to manipulate the immune environment in bone marrow and help for finding treatment approaches for hematopoiesis-based diseases, such as aplastic anemia. Utilizing cellular senescence to restrain tumor growth is discussed below.

**cGAS-STING PATHWAY IN INFECTION**

cGAS-STING signaling has an essential role in defense against a broad spectrum of intracellular DNA and RNA viruses (9, 26, 50). HIV is a typical RNA retrovirus: there is neither dsDNA in its genome, nor production of nucleic acids (50). Nevertheless, cGAS can detect the presence of HIV. RNA:DNA hybrids synthesized during reverse transcription that can be sensed by cGAS explain (at least in part) this phenomenon (14). cGAS may be triggered by endogenous DNA broken and released during HIV infection as well theoretically. However, some studies found the new mechanisms. The early reverse-transcription production of HIV-1 can flank short stem loops with paired base, which lead to the production of Y-type DNA containing unpaired guanosines that can activate cGAS well (15). Moreover, nucleolus protein non-POU domain-containing octamer-binding protein (NONO), as a sensor of capsid components of HIV, can help cGAS to be translocated to the nucleus and assist cGAS to sense HIV DNA accompanied by polyglutamine-binding protein 1 (PQBP1) (136, 137). The assistance proffered by NONO in assisting cGAS to sense DNA is also associated with its role in constructing a ribonuclear complex with DNA-dependent protein kinase (DNA-PK) subunits around hexamethylene bis-acetamide-inducible protein 1 (HEXIM1), termed as “HEXIM1-DNA-PK - paraspeckle components-ribonuclear protein complex (HDP-RNP),” which also has a role in repair of DNA damage and transduction of genotoxic signals (138). This complex is also required to accompany cGAS-PQBP1 in sensing DNA virus, such as Kaposi's sarcoma-associated herpes virus (139). In addition, during virus infection, STING activation can lead to global suppression of translation in cells, which restricts viral replication (140).

Compared with HIV-1, HIV-2 is less infective because it can infect dendritic cells (DCs) and elicit an anti-virus immune response. As a result, HIV-2 can cross-protect against HIV-1 (141). This phenomenon has been attributed to the fact that HIV-2 (instead of HIV-1) can encode protein Vpx, which overcomes the SAMHD1 restriction of dNTP in DCs (46, 142). HIV-1 can infect DCs via Vpx presentation, nevertheless, HIV-1 still cannot be fully sensed and induce an efficient immune response owing to certain escape mechanisms. Whether it is HIV-1 or HIV-2, a completely robust IFN response is required at pre- and post-integration sensing stages (143). cGAS in DCs can detect reverse-transcribed cDNA of HIV-2 before and after integration, whereas HIV-1 sensing is after genome integration owing to its capsid protection (144, 145). It was suggested that during initial infection by HIV-1, nucleotides are recruited into the intact capsid through the hexamer pores on the HIV-1 capsid. Therefore, the capsid-coated HIV-1 virus prevents the encapsidated reverse-transcription production from being sensed by the cytosolic nucleic-acid sensors (146). HIV-1 capsids can be ubiquitinated and then degraded by the host E3 ubiquitin ligase function of TRIM5, which leads to detection of viral DNA, meanwhile HIV-1 could use some host protein like cyclolinphils to evade the sensing (147, 148) (Figure 2A).

Similarly, other viruses also have evasion mechanisms to escape cGAS-STING pathway surveillance (Table 3). Therefore, identifying and preventing such viral-evasion factors could be a viable means to design novel anti-viral drugs.

cGAS-STING pathway is responsible to protect against intracellular or extracellular bacterial infection (especially...
### TABLE 3 | Virus productions associated with evasion from cGAS-STING pathway.

| Virus | Proteins | Targets | Functions | References |
|-------|----------|---------|-----------|------------|
| HSV-1 | UL41     | cGAS    | Selectively degrading cGAS mRNA | (316) |
|       | VP22     | cGAS    | Blocking cGAS enzymatic activity | (317) |
|       | UL37     | cGAS    | Deamidation | (318) |
|       | UL46     | STING   | NA | (319) |
|       | γ1 34.5 Protein | STING | Blocking translocation of STING | (320) |
| CMV   | UL31     | cGAS    | Disassociating DNA from cGAS | (321) |
|       | UL83     | cGAS    | Inhibiting cGAMP producing | (322) |
|       | UL48     | STING   | Cleaving K63-linked ubiquitin of STING | (323) |
|       | UL82     | STING   | Disrupting the STING-iRhom2-TRAPβ translocation complex | (324) |
|       | m152     | STING   | Blocking STING trafficking to Golgi | (325) |
|       | US9      | STING   | Disrupting STING oligomerization | (326) |
| KSHV  | ORF52    | cGAS    | Inhibiting cGAS enzymatic activity and interfering interaction between the HDP-RNP and cGAS | (327) |
|       | LANA     | cGAS    | Blocking cGAS enzymatic activity | (328) |
|       | vIRF1    | STING   | Blocking TBK1-STING interaction | (329) |
| Coronavirus | PLPro | STING   | Inducing an incomplete autophagy and degragation of STING and blocking STING-TRAF3-TBK1 complex formation and ubiquitination of STING | (330) |
| Poxivirus | F17 | cGAS    | Disrupting mTOR pathway to promote cGAS degradations and blocking STING trafficking | (331) |
|       | Poxins   | cGAMP   | Hydrolyzing cGAMP | (332) |
| Zika virus | NS1  | cGAS    | Cleaving K11-linked polyubiquitin chains from caspase-1 to promote the cleaving of cGAS | (333) |
| Dengue virus | NS2B3 | STING   | Promoting degradation of STING | (334) |
| HPV   | NS2B    | cGAS    | Promoting autophagy-dependent cGAS degradation | (335) |
| adenovirus | E7  | STING   | Inhibiting STING with LXCXE motif | (336) |
| Influenza A virus | E1A | STING   | Inhibiting STING with LXCXE motif | (337) |
| HCV   | NS4B    | STING   | Blocking interaction between STING and TBK1 | (338, 339) |
| HBV   | Pol     | STING   | Decreasing K63-linked polyubiquitination of STING | (340) |
| HIV   | vpx     | STING- NF-κB | Selectively suppressing STING-mediated NF-κB signaling | (341) |

HSV, herpes simplex virus; CMV, cytomegalovirus; iRhom2, inactive rhomboid protein 2; TRAPβ, translocon-associated protein β; KSHV, kaposi’s sarcoma-associated herpes virus; HDP-RNP, HEXIM1-DNA-PK-paraspeckle-components-ribonuclear protein complex; LANA, latency-associated nuclear antigen; vIRF1, viral interferon regulatory factor 1; PLPro, papain-like protease; LC3, light chain3; mTOR, mechanistic target of rapamycin; TRAF3, TNF receptor associated factor 3; HCV, hepatitis c virus; HPV, human papilloma virus; HBV, hepatitis B virus; HIV, human immunodeficiency virus; NF-κB, nuclear factor-κB.

Intracellular infections. CDNs (e.g., c-dGMP, c-dAMP, and cGAMP) produced by bacteria are essential for the regulation of bacterial function, such as biofilm formation, colonization, and reproduction (149, 150). As ligands for STING, CDNs can bind directly to and activate STING independently of cGAS, which contributes to several immune responses from bacteria (151). Usually, bacteria can enter or be engulfed by the cell through the endophagosome and be sequestered from the cytosolic sense receptor. Some bacteria, such as *Mycobacterium tuberculosis* (Mtb), can survive in vacuoles, resulting in an insufficient cellular immune response to defend against it (152). In contrast, the ESX-1 secretion system of the mycobacterium can translocate the phagosomal vacuolar matrix including bacterial genome molecules into the cytoplasm and trigger the cGAS-sensing pathway (153). For other bacteria, such as *Legionella pneumophila* or and *Brucella abortus*, the host guanylate binding proteins (GBPs) facilitate rupture of phagosome vacuoles and are indispensable for controlling their infection (154, 155). Autophagy signaling mediated by cGAS/STING is also involved in microorganism clearance mentioned above (90, 91).

Bacteria have evolved strategies to confront this pathway too. Bacterial phosphodiesterase CdnP produced by Mtb or group-B streptococci can degrade CDNs (156, 157). CpsA (a type of Mtb LytR-CpsA-Psr domain-containing protein) can prevent autophagy responses for eliminating pathogens (90). *Chlamydia trachomatis* inclusion membrane proteins can maintain the stability of the inclusion membrane and avoid inclusion lysis (leading to pathogen antigens leaking out and being detected by the host cell) (158, 159). *Yersinia* outer protein J (YopJ) deubiquitinates STING and impedes the formation of the STING signalosome (160). The cGAS-STING pathway activation even impedes the elimination of *Listeria monocytogenes* because bacterial DNA can be packaged into EVs and transferred into T cells, where it induces apoptosis of T cells (161, 162).

Several protozoans, such as *Toxoplasma gondii* and malaria parasites, have an intracellular period in their lifecycle. *T. gondii* could engage cGAS-STING exclusively (163).
However, IRF3 activation inducing ISG expression promotes *T. gondii* development independently of IFN expression (163). *P. falciparum* can target erythrocytes, lacking a nucleus and unable produce IFN, but infected erythrocytes can secrete EVs containing parasitic gDNA to monocytes and trigger cGAS (164).

**cGAS-STING PATHWAY IN AUTOIMMUNE OR INFLAMMATORY DISEASES**

The immune system is regulated by a complicated network. Disorder of immune signaling can elicit non-infectious inflammatory or autoimmune diseases. Excessive, uncontrolled production of type-I IFN can lead to a spectrum of inflammation diseases termed “type-I interferonopathies,” which have some common manifestations (165). cGAS-STING is the one of main sources of type-I IFN, acts as a cellular immune-sensing signaling axis, and is involved in type-I interferonopathies.

Stimulator of interferon gene-associated vasculopathy with onset in infancy (SAVI) is a typical STING-related hereditary inflammatory type-I interferonopathy, and is manifested by interstitial lung disease, dermatomyositis and arthritis. Its pathology is featured by leukocytoclastic vasculitis and microthrombotic angiopathy of small dermal vessels (166, 167) and patients can also suffer from lymphopenia (166–169). The etiology of SAVI is a gain of function (GOF) mutant in STING which leads to constitutive STING activation without CDNs stimulation (166). Currently, several mutant amino acids residues have been found in or close to the dimerization domain (V155M, N154S, G166E, V147L, and V147M) (64, 166, 168, 170), as well as R284G, R284S, R281Q, and C206Y in the cGAMP-binding domain (171).

Other types of type-I interferonopathies, such as systemic lupus erythematosus (SLE) and Aicardi–Goutières syndrome (AGS), have relationships with defective clearance of cytosolic nucleic acids caused by congenital dysfunction of TREX1, RNASEH2, and SAMHD1. SLE is a heterogeneous autoimmune disease which has prominent type-I and also -II IFN signatures (172). AGS comprises some systemic autoimmune syndromes overlapping with SLE, and can be classified as a “lupus-like disease” (173). Additionally, AGS also causes severe developmental neurological disorders, including cerebral calcifications, encephalopathy and cerebral atrophy.

Systemic lupus erythematosus is a representative model for elucidating the mechanism of type-I interferonopathies. In SLE, the level of self-DNA which is packaged into apoptosis-derived membrane vesicles along with the level of anti-dsDNA antibody is increased in the serum of patients (174). A study revealed increasing levels of ISGs (including cGAS/STING) as well as the cGAMP-detected ratio in peripheral-blood mononuclear cells of SLE patients (175). As innate immune cells, DCs have essential roles in antigen presentation, cytokine secretion, and priming the adaptive response of immune cells (176). Plasmacytoid DCs (pDCs) can internalize and recognize self-DNA and they are the main source of type-I IFN in serum during SLE (177). IFNα/β is essential for complete function of immature pDCs (178). IFNα/β and IL-1 can induce mitochondrial oxidative stress in DCs and decrease ATP production, which blocks proton-pump function and increases pH of lysosomes. This process inhibits mitochondrial degradation and blocks mtDNA clearance, which engages the cGAS-STING pathway (31, 179). Moreover, monocytes may sense mtDNA through cGAS-STING and differentiate into DCs (31, 180). Neutrophil extracellular traps (NETs) are complexes released by neutrophils exposed to stimuli or autoantibody immune complexes. NETs comprise extracellularly released chromatin, myeloperoxidase enzymes, and also oxidized mtDNA. In lupus-like diseases, NETs can be induced by IFNα/β and may play a major part in priming pDCs (181, 182). All mechanisms stated above contribute to a more aggravated type-IIIFN response and exacerbate disease. A similar phenomenon can be observed in SAVI, ataxia telangiectasia (AT) and Artemis deficiency (183). However, compared with SAVI, DCs in SLE can prime T-cell maturation significantly and increasing secretion of pro-inflammatory cytokines, such as IL-6 and TNFα can also lead to activation of adaptive immunity (Figure 4A).

The cGAS-STING pathway can mediate systemic inflammation as well as autoimmune activation. However, it is also involved in the local inflammation of multiple tissues. With regard to ischemic myocardial infarction (MI), cardiac macrophages can sense dying ruptured cells and lead to fatal post-MI cardiac inflammation, which is reversed by ablation of cGAS/STING/IRF3 (184, 185). In a non-alcohol steatohepatitis (NASH) model induced by a methionine- and choline-deficient or high-fat diet, lipotoxicity can cause mitochondrial damage and up-regulate STING/IRF3 expression in hepatocytes, which in turn promotes lipid accumulation and inhibits glycogen synthesis. All above bring out hepatic inflammation and hepatocytes apoptosis (186). In this model, mice with deficiency of STING presents alleviated insulin resistance and lower levels of low-density lipoprotein in serum, and also decreased hepatic inflammation and fibrosis/steatosis, in which hepatic macrophages/kupffer cells may take a big part (187, 188). Lipotoxicity can induce p62 to be phosphorylated through the cGAS-STING-TBK1 pathway, which causes aggravated protein inclusions in hepatocytes and it indicates that p62 could be a biomarker for NASH prognosis (189). mtDNA-dependent inflammation induced by lipotoxicity also occurs in adipose tissue and endothelial cells of blood vessels, which contributes to tissue inflammation, insulin resistance, and cardiovascular diseases (42, 190). In traumatic brain injury (TBI), local injury initiates breakdown of the blood–brain barrier and global neuroinflammation (191). STING expression is up-regulated in TBI and can lead to increased expression of pro-inflammatory cytokines and enlargement of secondary injury (192). Reduced autophagy-associated protein expression induced by STING may contribute to the dysfunction of autophagy and dampen the elimination of necrotic tissue, thereby intensifying inflammation (192). During silicosis, silica can yield cytosolic dsDNA release and engage cGAS-STING, which activates DCs and macrophages to cause severe lung inflammation. It also leads to death of epithelial cells through the NLRP3 pathway and pulmonary fibrosis (193). Similarly, mtDNA release in renal tubule cells has...
FIGURE 4 | Activation of the cGAS-STING pathway can induce type-I interferonopathies or adaptive immune deficiency. Stimulator of interferon genes (STING) can be stimulated by cyclic dinucleotides (CDNs), agonist compounds and mutants. (A) STING activation in dendritic cells (DCs). When exposed to type-I interferon (IFN), neutrophils can release neutrophil extracellular traps (NETs). DCs can internalize self-DNA and trigger the cyclic-GMP-AMP synthase (cGAS)-STING pathway to secrete type-I IFN, which activates DC maturation. Type-I IFN in turn induces mitochondrial stress and decreases ATP production that increases the pH of lysosomes. Incomplete degradation of mitochondria leads to accumulation of mtDNA in the cytosol and activates STING. Mature DCs can present antigen and co-activate signaling to prime T cell-mediated adaptive immune responses. (B) STING activation in T cells. IFNα/β enhances differentiation of T helper 2 (Th2) cells but suppresses differentiation of Th1 cells. Activation of STING can induce mitotic delay and unfolded protein response (UPR), leading to reduced proliferation and promotion of apoptosis. All of the actions stated above suppress the functions of Th1 cells and lead to suppression of adaptive immune responses (Red arrows represent mechanisms limiting cellular immune responses, and black arrows represent mechanisms promoting cellular immune responses).

been found to be associated with acute kidney injury by cytotoxic drugs and chronic renal fibrosis (194, 195).

Neurodegenerative diseases are correlated with local inflammation (196). In the central nervous system (CNS), microglia is considered to be the main source of cGAS-STING-dependent IFN expression (197). In neurodegenerative diseases, levels of the marker of microglia activation-cluster of differentiation 68 (CD68), and pro-inflammatory cytokines are increased (198). A significant feature of Parkinson's disease (PD) is the neuronal loss of cerebral nuclei (especially dopaminergic neurons in the substantianigra). Serine/threonine-protein kinase PINK1 and E3 ubiquitin-protein ligase parkin are ubiquitin-related factors that take part in removing damaged mitochondria by autophagy, and their dysfunction lead to the early onset of PD (199). Parkin<sup>−/−</sup> and PINK1<sup>−/−</sup> mice, following exhaustive exercise, show inflammation and loss of dopaminergic neurons, which can be rescued by loss of STING (200). Similarly, AT is a genetic disease caused by missense mutation of a DNA-repair protein: ATM. AT patients usually show neurodegenerative defects (especially ataxia) complicated with telangiectasia on their eyes or body, deficiency of adaptive immune cells, and predisposition to cancer (201). Nevertheless, up-regulation of expression of type-I IFN can also be found in AT patients and mice, causing them to be prone to autoimmune diseases (36, 183, 202). This syndrome is related to p53-mediated senescence but also the chronic inflammation mediated by the cGAS-STING pathway which engages cytosolic uncombined broken gDNA caused by ATM dysfunction (127). In addition, accumulation of cellular mtDNA occurs in age-related macular degeneration characterized by retinal pigment epithelium (RPE) degeneration. This can trigger chronic inflammation by cGAS-STING pathway, in which NLRP3 inflammasomes, inflammatory/apoptotic caspases are also involved (203, 204).

With regard to other diseases in which adaptive immune cells prime, cGAS-STING has a different role. Multiple sclerosis (MS) is a local inflammatory disease of CNS. MS is characterized
by over-reactive microglia, infiltration of self-reactive T cells, demyelization of nerve fibers and hyperplasia of gliocytes. Autoantibodies against proteins expressed in immune-privileged regions of CNS also contribute to its pathogenesis (205). In MS, IFNα/β can attenuate disease severity effectively. This implies a protective role for type-I IFN in CNS, which is considered to counteract the pro-inflammatory IFNγ (206). Using experimental autoimmune encephalitis (EAE) as a MS model, STING was found to be indispensable for amelioration of type-I IFN-mediated neuroinflammation, and it could be induced by a conventional anti-viral drug ganciclovir (207). Ultraviolet (UV) radiation is a factor inversely related to the morbidity of MS (208). It was found that UV-B irradiation can recruit inflammatory monocytes and produce type-I IFN in a STING-dependent manner (209). All above indicate that cGAS-STING-IFNα/β pathway may have a beneficial effect on some CNS inflammatory diseases such as MS.

A possible reason for the observed effect above is due to indoleamine 2,3-dioxygenase (IDO), which can catabolize tryptophan (Trp) oxidatively. Trp withdrawal or Trpoxidative catabolites can interact with general control non-deressitable 2 (GCN2) and mTOR, of which both can control cellular amino-acid metabolism and suppress T helper 1 (Th1) cells immunity (210). IFNα/β is a potent IDO inducer to suppress proliferation of CD4+ Th1 cells and promote differentiation of Foxp3+ regulatory T (Treg) cells, which are believed to suppress CNS-specific autoimmunity (210, 211). In addition, DNA released from dying cells can be internalized directly by T cells and sensed by cGAS-STING pathway, which leads to enhancement of the Th1/2 transcription factor GATA3 but suppression of the Th1 transcription factor T-bet. Consequently, this process polarizes naive T cells toward Th1/2 differentiation (212). Studies mentioned above may (at least in part) explain why the cGAS-STING signal is a negative regulator of MS.

The inhibitory role of cGAS-STING in inflammation is also attributed to its apoptosis-triggering role. In some subtypes of SAVI and mouse models, apoptosis of blood-vessel endothelial cells or bronchial epithelial cells and leucopenia can be observed (especially T-cell lymphopenia) (166, 169, 170). When the STING signal is stimulated, apoptosis occurs more frequently in normal or cancerous T cells (119). Also, bone-marrow chimeras and gene-knockout studies have shown that T cells defect in SAVI are not associated with type-I IFN signaling or cGAS (213, 214). Localization of STING at the Golgi can cause delay of T-cell mitosis and reduced proliferation independently of IRF3 and TBK1 (215). Furthermore, a “UPR motif” on the C-terminus of STING can cause ER stress and UPR, resulting in Ca²⁺ overloading and T-cell death (82). A controversial view is that B cells express STING variably and may undergo apoptosis through this way (166, 216, 217). However, simultaneous signaling by STING and the B-cell antigen receptor can promote B-cell activation and antibody production independently of type-I IFN (217) (Figure 4B).

As for some diseases with inflammatory responses involved, the acute phase of pancreatitis causes dying acinar cells to produce free dsDNA, which activates cGAS-STING signaling in macrophages, and exacerbates inflammation severity (218). However, in the chronic phase of pancreatitis, cGAS-STING activation decreases pancreatic inflammation, which may be mediated by limiting Th17 response (219). For gut mucosal immunity, transient stimulation of STING could strengthen the function of antigen-presenting cells (APCs) and promote Th1 and Th17 immune responses against microbes (220). Chronic STING signaling, however, elicits an IL-10 response to control the inflammation and avoids inflammatory enterocolitis such as bowel disease (221). STING knockout mice present reduced numbers of goblet cells, a decreased ratio of commensal versus harmful bacteria and compromised Treg cells in the gut, making it prone to enterocolitis (222).

**cGAS-STING PATHWAY IN CANCER**

Chromosomal instability (CIN) is an intrinsic feature of cancer, and results spontaneously from errors in chromosome segregation during the mitosis of cancer cells. CIN can also be induced manually by radiotherapy or chemotherapy, which causes DSBs. It results in micronuclei formation outside the nucleus, of which rupture brings out irrepressible accumulation of cytosolic self-DNA and engages cGAS (32, 38, 223). However, normal mitotic processes involve exposure of chromosomal DNA to the cytoplasm, but this cannot initiate a substantial inflammatory reaction or apoptosis because nucleosomes can suppress dsDNA-cGAS binding in a competitive manner (41).

An appropriate immune response against tumors via a type-I IFN plays an indispensable part in limiting tumors and prolonging host survival (224). It was found STING-deficient mice are prone to developing several types of cancer and have poor survival under a tumor burden, whereas stimulation of STING can elicit robust immunity to tumors (225–227). A mechanism is many cancer cells expressing cGAS can recognize cytosolic DNA and produce cGAMP to stimulate secretion of type-I IFN through STING (228, 229). Excessive expression of TREX1 in cancer cells, which can be induced by radiotherapy, attenuates this progression (228). cGAS-STING can also promote senescence of cancer cells through the p53-p21 pathway (129). cGAS-STING-mediated autophagy contributes to autophagic cell death if mitotic crisis occurs to avoid transformation of cancer cells (121). Melanoma cells can also transfer cGAMP produced by them to proximal non-cancerous host cells through gap-junction channels and activate STING in these cells, which contributes to the recruitment of tumor-infiltrating immune cells such as natural killer (NK) cells (51, 230). Expression of the NK cell-specific ligand NKG2D retinoic acid early transcript 1 (RAE1) on cancer cells is highly up-regulated by STING once NK cells permeate into tumor tissue (231). The activation of STING in the endothelium within the tumor microenvironment (TME) could contribute to the remodeling of tumor vasculatures, and may have positive effects on tumor regression (232).

Dendritic Cells are the main source of type-I IFN in several types of TMEs and are dependent on STING signaling (229). More preferentially than macrophages, infiltrating DCs take up tumor-derived DNA or cGAMP from dying cell fragments by phagocytosis (27, 29, 129, 226, 233). Moreover, cancer
cells can package DNA into exosomes and transfer DNA to DCs (234). Produced cGAMP by cancer cells can also be transferred to DCs through forming gap junction (53). By activating cGAS-STING signal in DCs, CD8α+ subtype DCs secret chemokines such as CCL5 and CXCL10 and cross-prime infiltrating anti-tumor CD8+ T cells (29, 226, 235–237). In contrast, numbers of immune-suppressing cells such as Treg cells, myeloid-derived suppressor monocytes and M2 macrophages have been reported to be decreased (225, 238, 239). Expression of IL-15/IL-15Rα complex is up-regulated in myeloid cells with the help of STING/type-I IFN and promotes tumor regression (240).

Tumor cells can evade intrinsic cellular surveillance in different ways. In various cancer cell lines, cGAS, STING, TBK1, and IRF3 are mutated frequently and their decreased expressions are also related to the high level of methylation (241). STING expression has been shown to be suppressed by the alternative lengthening of telomeres (ALT) pathway, which is responsible for prolonging the telomere length and maintaining the proliferation of tumor cells (242). A hypoxic environment in tumor cells can lead to accumulation of lactic acid and is associated with the inhibition of tumor-conditional DCs and reduced expression of IFN signaling molecules (243). In breast cancer, functional up-regulation of expression of human epidermal growth factor receptor 2 (HER2), a ligand-independent receptor tyrosine kinase (RTK), can arrest the expression of RAC-alpha serine/threonine-protein kinase (AKT1) (a key factor in the mTOR pathway), which is reported to inhibit the activation of cGAS and TBK1 (244, 245).

Patients with lung adenocarcinoma have a low probability of survival if they have reduced expression of cGAS (132). Thus, expression of the cGAS-STING and DNA-damage marker histone γH2AX in tumor cells could be considered as independent prognostic factors to predict therapy response and clinical outcome, and could be superior to that of traditional markers like immunogenic cell death and T cells number (246).

However, some scholars have arrived at opposite conclusions. When DSBs occur in cancer cells, cGAS can be relocated to the nucleus and obstruct the formation of the PARP1-Timeless complex, thereby inhibiting homologous recombination repair and maintaining CIN, which potentiates tumor evolution (35, 223). It has also been reported that cGAS recognizing CIN activates non-canonical NF-κB signaling and potentiates cellular metastasis programs (247). Furthermore, STING−/− mice are resistant to skin carcinogenesis in a 7,12-dimethylbenz(a)anthracene (DMBA)-treatment model. It has been demonstrated that when DMBA-induced nuclear DNA leaks into the cytoplasm, STING can induce chronic inflammatory stimulation that contributes to cancer development (248). During brain metastasis, cGAMP transferred to bystander cells (e.g., astrocytes) can also produce IFNα and TNFα in the TME but, in this context, it will support tumor development and chemoresistance (249). Coordinating with myeloid cells penetrating into the tumor, myeloid-derived suppressor cells can also be recruited through the C-C chemokine receptor type 2 (CCR2) (250). Another study found that microparticles yielded by tumor cells can turn macrophages into the M2 type through cGAS-STING-TBK1, contrary to previous findings (251).

Immune-system interactions with tumor cells are complicated. The effect of cGAS-STING on cancer is dependent on the type of tumor, host immune state, activated cell types, therapeutic intervention, and the magnitude of cGAS-STING activation. Like inflammation generated by cGAS-STING, a time-dependent inflammatory anti-tumor response mediated by cGAS-STING may be present. Temporary activation of cGAS-STING in innate immune cells could enhance the anti-tumor effect, whereas sustained activation of cGAS-STING might induce immune tolerance of the tumor. More investigations are necessary to ascertain the exact role of cGAS-STING in oncology, and elucidate the specific advantages and adverse effects of targeting the cGAS-STING pathway in cancer therapy (Figure 5).

**TARGETING THE cGAS-STING PATHWAY FOR TREATMENT**

Considering the pivotal role of the cGAS-STING pathway in infection, inflammation and cancer, positive modulation of the pathway signaling is a promising way to enhance the immune state and restrict microorganisms or heterogeneous cells, whereas negative modulation can control aberrant inflammation.

Radiotherapy or chemotherapy drugs such as cisplatin or cyclophosphamide can induce DSBS and micronuclei, then trigger the cGAS-STING pathway to enhance tumor immunogenicity (252–254). In addition, PARP inhibitors such as olaparib have promising effects on cancer cells lacking BRCA2 because of their cooperative DNA-repair functions (253). Although cGAS activation is inhibited by nucleosomes, taxol can induce mitotic cell-cycle arrest and sustain divided chromatin in the cytosol to activate the cGAS-STING pathway slowly, and accumulation of signaling could stimulate apoptosis of cancer cells (41). Inhibitors of topoisomerase 1 or 2 used conventionally as chemotherapy drugs trigger minor damage to DNA and accumulation of cytosolic DNA, which can engage cGAS and enhance the anti-tumor or anti-infection responses of cells (255–257).

cGAS-STING is essential on anti-tumor immune checkpoints therapies. For example, blockade of CD47-signal regulatory protein α (SIRPα) signaling on DCs can activate NADPH oxidase 2 (NOX2) and increase the pH in phagosomes along with incomplete degradation of mtDNA, which can trigger cGAS-STING (129). STING deficiency in mice abrogates the anti-tumor effect of CD47 blockade (258). A similar phenomenon also can be seen in anti-programmed cell death-1 (PD-1) therapy (259). There is greater infiltration of INFγ+ cells and CD8+ T cells and PD-1/PD-1 ligand 1 (PD-L1) expression in TME treated by STING-ligand derivatives (260). Therefore, in several types of tumors, combined administration of a STING agonist and immune-checkpoint antibody could elicit a more curative outcome compared with one therapy alone (238, 261).

Viruses can infect cells lacking cGAS-STING more effectively, and have higher oncolytic activity compared with virus
FIGURE 5 | Cell interactions in TME engaging the cGAS-STING pathway. Double-stranded breaks (DSBs) can lead to cytosolic self-DNA that engages the cyclic-GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway and produces type-I interferon (IFN). STING promotes the senescence of cancer cells. Cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) can transfer to proximal host non-cancer cells through gap-junction channels and promote the formation of an inflammatory tumor microenvironment (TME). Dendritic cells (DCs) are the main source of type-I IFN and tumor necrosis factor α (TNFα), and promote an inflammatory TME. Infiltrating DCs take up tumor-derived DNA or cGAMP from dying cell fragments or exosomes. DCs cross-prime and activate anti-tumor cluster of differentiation 8 (CD8$^+$) T cells and constrict cancer growth effectively. Co-stimulation of type-I IFN and TNFα signaling simultaneously leads to remarkable necroptosis of tumor cells. cGAS can relocate to the nucleus and obstruct polymerase 1 (PARP1), which suppresses DNA repair. Chronic levels of IFNα and TNFα in TME could support tumor development and cause type-2 macrophages and regulatory T cells to be recruited (Red arrows represent mechanisms promoting tumors; black arrows represent mechanisms limiting tumors).

therapy alone. Hence, the use of oncolytic viruses such as talimogene laherparepvec is beneficial for treating tumors with low expression of cGAS/STING. STING expression can be regarded as a prognostic measurement for such therapy (262).

Some artificial analog molecules of CDNs, such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and 10-carboxymethyl-9 (10H) acridone (CMA) can bind the CDN pocket of mouse-specific STING dimers and promote conformational transition of STING from inactive "open" to an active "closed" state (263, 264). DMXAA showed convincing efficacy in restraining tumors in mice (265). However, DMXAA is restricted in activating mouse-specific STING but not human-specific STING, which could be an explanation for the failure of DMXAA in treating 1299 non-small-cell lung cancer patients in a phase-III clinical trial (NCT00662597) (266). Nonetheless, with three substitutions (G230I, Q266I, and S162A), human STING can also be induced by DMXAA to undergo conformational transition (264). Another new compound, amidobenzimidazole, has been found to be an agonist of STING without lid closure and has potential therapeutic value (267).

Cyclic dinucleotides and their derivates that can stimulate STING directly are candidate adjuvants to restrain tumors. Intratumoral administration of c-dAMP, c-dGMP, or cGAMP analogs alone or combined with other adjuvants or tumor antigens have shown anti-tumor effects (259, 268); phase-I or II clinical trials (NCT02675439, NCT03172936, and NCT03937141) of dithio-(RP,RP)-c-dAMP (known as ADU-S100) are ongoing (261). To avoid the degradation and ensure maximal phagocyte internalization of CDNs, endosomolytic nanoparticles have been designed to package and deliver CDNs. For example, pH-sensitive nanoparticles (e.g., STING-nanoparticles) can release their contents if located in acidic endosomal environments (269).

For treatment of type-I interferonopathies, lessons can be taken from the treatment of canonical autoimmune disease such as SLE, but there are several differences. For example, it was found that corticosteroid pulse therapy, γ-immunoglobulins, disease-modifying anti-rheumatic drugs, anti-CD20, and some
immunosuppressants (e.g., methotrexate) have limited efficacy against SAVI (166, 171). JAK inhibitors such as ruxolitinib, tofacitinib and baricitinib that reduce type-I IFN downstream signaling have shown therapeutic value against SAVI, but further verification of their efficacy is needed (270). Moreover, novel immune therapies, such as anti-IFNαs and anti-IFNAR immunoglobulin, are in clinical trials for SLE. These could also be tested against SAVI in the future (165).

Pharmacologically screening has revealed that some antimalaria drugs, such as suramin, have an inhibitory effect on cGAS by blockade of interaction between DNA and cGAS (271). In addition, novel small molecules such as RU320521 or G150 can occupy the enzymatic pocket of species-specific cGAS to abrogate cGAMP synthesis (272, 273). Recently, a study found that aspirin can acetylate cGAS at three lysine residues and block cGAS activity (274). With regard to STING, the cyclopeptide Astin C can block IRF3 recruitment onto the STING signalosome (275). The molecule H-151 can block the palmitoylation of human-STING (276). All of these agents are potential candidates for alleviating type-I interferonopathies.

CONCLUDING REMARKS AND FUTURE PERSPECTIVES

The cGAS-STING pathway is primarily responsible for the modulation of immune response in cells when facing cytosolic dsDNA challenge. Moreover, it is complicatedly cross-regulated by other cellular processes or cellular signaling networks. The exact fundamental mechanism of the pathway in cells and the effect on the whole organism in specific states is not completely clear and requires further investigation.

In conclusion, the cGAS-STING pathway has dichotomous roles in the immune system. In general, cGAS-STING-type-I IFN signaling can promote the innate immune response in myeloid cells but alleviate the adaptive immune response exerted by T cells and B cells. cGAS shows high expression in APCs such as macrophages and DCs, but STING is expressed in most cells (10). cGAS-STING signaling corresponding to cytoplasmic dsDNA in APCs can boost innate and adaptive immunity transiently. In this situation, the DNA challenge signal is limited to only macrophages and DCs. Their pro-inflammatory and antigen-presenting functions to adaptive immune cells are promoted in the short-term. If the signal spreads to other bystander cells, such as T cells, B cells, local resident cells by means of cGAMP transfer, or just aberrant STING activation by GOF, it causes apoptosis in bystander cells or adaptive immune cells and immune tolerance in the long-term. Therefore, it is reasonable to conclude that the intrinsic function of the cGAS-STING pathway is essential for the innate immune system responses of the host immediately after pathogen invasion or abnormal cell appearing. Once the challenge persists, the cGAS-STING pathway controls the adaptive immune system to avoid chronic, detrimental inflammatory reactions or autoimmune diseases.

The inflammatory response exists universally in almost all physiologic and pathologic progressions. cGAS-STING is pivotal in modulating cellular inflammation, so it is promising to extend our conception of the cGAS-STING pathway onto more diseases with inflammatory responses involved, especially CNS-based diseases such as stroke, in which the inflammatory reaction exists but was recognized less.

Moreover, for targeting the cGAS-STING pathway for therapeutic purposes, drugs should be optimized to augment the desirable effect and prevent its unwanted effects. For example, to eliminate tumor cells or infectious agents, agonists of cGAS-STING would be a rational option if designed to target APCs exclusively but not T cells or B cells. In this scheme, the anti-tumor immune response is enhanced while avoiding apoptosis of adaptive immune cells and infiltration of immune suppressor cells. Also, most research on the cGAS-STING pathway has focused on its IFN-expressing role but overlooked autophagy and cell-death roles, which are also main downstream signaling of the pathway. Therefore, some drugs, such as emricasan, are potential apoptosis inhibitors that may have a complementary effect on ameliorating apoptosis of blood-vessel endothelial cells or bronchial epithelial cells, and lymphopenia, in SAVI.

Until now, studies of the cGAS-STING pathway have been done mainly in the laboratory but it has large space to be explored in clinical or translational fields. Additionally More PRRs and cellular immune-surveillance pathways may remain to be discovered to piece together the molecular puzzles of the cell.

AUTHOR CONTRIBUTIONS

DW drafted the manuscript and drew the figures. WJ and JH conceived and revised the review.

FUNDING

This work was supported by the National Natural Science Foundation of China (81571600, 81322018, and 81273287 to JH).

ACKNOWLEDGMENTS

We thank K. wood from Barrow Neurological Institute for discussions and editing.

REFERENCES

1. Roers A, Hiller B, Hornung V. Recognition of endogenous nucleic acids by the innate immune system. Immunity. (2016) 44:739–54. doi: 10.1016/j.immuni.2016.04.002

2. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. (2008) 455:674–8. doi: 10.1038/nature07317

3. Zhong B, Yang Y, Li S, Wang YY, Li Y, Diao F, et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor...
activation. *Immunity.* (2008) 29:538–50. doi: 10.1016/j.immuni.2008.09.003

4. Sun W, Li Y, Chen L, Chen H, You F, Zhou X, et al. ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimethylation. *Proc Natl Acad Sci USA.* (2009) 106:6653–8. doi: 10.1073/pnas.0900850106

5. Woodward JJ, Iavarone AT, Portnoy DA. C-di-AMP secreted by intracellular *Listeria monocytogenes* activates a host type I interferon response. *Science.* (2010) 328:1703–5. doi: 10.1126/science.1189801

6. Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M, et al. STING is a direct innate immune sensor of cyclic di-GMP. *Nature.* (2011) 478:515–8. doi: 10.1038/nature10624

7. Unterholzner L, Keating SE, Baran M, Horan KA, Jensen SB, Sharma S, et al. IFI16 is an innate immune sensor for intracellular DNA. *Nat Immunol.* (2010) 11:997–1004. doi: 10.1038/ni.1932

8. Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP–AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. *Science.* (2013) 339:786–91. doi: 10.1126/science.1232458

9. Li XD, Wu J, Gao D, Wang H, Sun L, Chen ZJ. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. *Science.* (2013) 341:1390–4. doi: 10.1126/science.1244040

10. Mabbott NA, Baillie JK, Brown H, Freeman TC, Hume DA. An expression atlas of human primary cells: inference of gene function from coexpression networks. *BMC Genomics.* (2013) 14:632. doi: 10.1186/1471-2164-14-632

11. Whiteley AT, Eaglesham JB, de Oliveira Mann CC, Morehouse BK, Lowey P, Niemanen EA, et al. Bacterial cGAS-like enzymes synthesize diverse nucleotide signals. *Nature.* (2019) 567:194–9. doi: 10.1038/s41586-019-0953-5

12. Civile F, Deimling T, de Oliveira Mann CC, Ablasser A, Moldt M, Witte G, et al. Structural mechanism of cytosolic DNA sensing by cGAS. *Nature.* (2013) 498:332–7. doi: 10.1038/nature12305

13. Kranzusch PJ, Lee AS, Berger JM, Doudna JA. Structure of human cGAS reveals a conserved family of second-messenger enzymes in innate immunity. *Cell Rep.* (2013) 3:1362–8. doi: 10.1016/j.celrep.2013.05.008

14. Mankan AK, Schmidt T, Chauhan D, Goldeck M, Honing K, Gaidt M, et al. Cytosolic RNA:DNA hybrids activate the cGAS-STING axis. *EMBO J.* (2014) 33:2937–46. doi: 10.15252/embj.201448726

15. Herzner AM, Hagmann CA, Goldeck M, Wolter S, Kubler K, Wittmann M, et al. Sequence-specific activation of the DNA sensor cGAS by Y-form DNA. *EMBO J.* (2019) 38:1060–7. doi: 10.15252/embj.201812676

16. Heijink AM, Talens F, Jae LT, van Gijn SE, Fehrmann RSN, Brummelkamp TR, et al. BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity. *Nat Commun.* (2019) 10:100. doi: 10.1038/s41467-018-07927-y

17. Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA. Mitotic progression following DNA damage enables pattern recognition signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity. *Nature.* (2015) 520:553–7. doi: 10.1038/nature14156

18. Price BD, D’Andreà AD. Chromatin remodeling at DNA double-strand breaks. *Cell.* (2013) 152:1344–54. doi: 10.1016/j.cell.2013.02.011

19. Liu H, Zhang H, Wu X, Ma D, Wu J, Wang L, et al. Nuclear cGAS suppresses DNA repair and promotes tumorigenesis. *Nature.* (2018) 563:131–6. doi: 10.1038/s41586-018-0629-6

20. Hartlova A, Erttmann SF, Raffi FA, Schmalz AM, Resch U, Anugula S, et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. *Nature.* (2017) 549:394–8. doi: 10.1038/nature23890

21. Zierhut C, Yamaguchi N, Paredes M, Luo JD, Carroll T, Funabiki H. The catalytic domain of human cGAS catalytic domain has an additional DNA-binding interface that enhances enzymatic activity and liquid-phase condensation. *Proc Natl Acad Sci USA.* (2019) 116:11946–55. doi: 10.1073/pnas.1905031116

22. Jeurink VC, Coronas-Serna JM, Zhou W, Ermandes MJ, Cao A, Kranzusch PJ, et al. Phosphoinositide interactions position cGAS at the plasma membrane to ensure efficient distinction between self- and viral DNA. *Cell.* (2019) 176:1432–46.e11. doi: 10.1016/j.cell.2019.01.049

23. Luecke S, Holleufer A, Christensen MH, Jonson KL, Boni GA, Sorensen LK, et al. cGAS is activated by DNA in a length-dependent manner. *EMBO Rep.* (2017) 18:1707–15. doi: 10.15222/embre.201744017

24. Schoggins JW, MacDuff DA, Imanaka N, Gainey MD, Shrestha B, Eitson JL, et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. *Nature.* (2014) 505:691–5. doi: 10.1038/nature12862

25. Ahn J, Xia T, Rabasa Capote A, Betancourt D, Barber GN. Extrinsic phagocytosis-dependent STING signaling dictates the immunogenicity of dying cells. *Cancer Cell.* (2018) 33:862–73.e5. doi: 10.1016/j.ccell.2018.03.027

26. Diao J, Li T, Li XD, Chen X, Li QZ, Wight-Carter M, et al. Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases. *Proc Natl Acad Sci USA.* (2015) 112:E5999–7. doi: 10.1073/pnas.1516451112

27. Gkirtzimanaki K, Kabran E, Nikoleti D, Polyzos A, Blanas A, Sidiroopoulos P, et al. IFNalpha impairs autophagic degradation of mtDNA promoting autoimmunity in SLE monocytes in a STING-dependent fashion. *Cell Rep.* (2018) 25:921–33.e5. doi: 10.1016/j.celrep.2018.09.001

28. Hartlova A, Erttmann SF, Raffi FA, Schmalz AM, Resch U, Anugula S, et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immune response. *Immunity.* (2015) 520:553–7. doi: 10.1016/j.immuni.2014156

29. Kranzusch PJ, Lee AS, Berger JM, Doudna JA. Structure of human cGAS reveals a conserved family of second-messenger enzymes in innate immunity. *Nature.* (2010) 328:1703–5. doi: 10.1126/science.1189801

30. Xie W, Lama L, Adura C, Tomita D, Glickman JE, Tuschl T, et al. Human cGAS catalytic domain has an additional DNA-binding interface that
43. White MJ, McArthur K, Metcalfe D, Lane RM, Cambier JC, Herold MJ, et al. Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. *Cell* (2014) 159:1549–62. doi: 10.1016/j.cell.2014.11.036

44. Snyder HR, Kaiser RH, Warren SL, Heller W. Obsessive-compulsive disorder is associated with broad impairments in executive function: a meta-analysis. *Clin Psychol Sci* (2015) 3:301–30. doi: 10.1177/216770121543210

45. Mackenzie KJ, Carroll P, Lettice L, Tarnaukaite Z, Reddy K, Dix F, et al. Ribonuclease H2 mutations induce a cGAS-STING-dependent innate immune response. *EMBO J* (2016) 35:831–44. doi: 10.15252/embj.201593339

46. Maelfaft J, Bridgeham A, Belnahrach A, Cursi C, Rewinkel J. Restriction by SAMHD1 limits GAS-STING-dependent innate and adaptive immune responses to HIV-1. *Cell Rep* (2016) 16:1492–501. doi: 10.1016/j.celrep.2016.07.002

47. See A, Belgnauoui SM, Olagnier D, Lin R, Hiscott J, van Grevenynghe J. Host restriction factor SAMHD1 limits human T cell leukemia virus type 1 infection of monocytes via STING-mediated apoptosis. *Cell Host Microbe* (2013) 14:422–34. doi: 10.1016/j.chom.2013.09.022

48. Coquel F, Silva MJ, Techer H, Zadorozhny K, Sharma S, Niemuniszczyj C, et al. SAMHD1 acts at stalled replication forks to prevent interferon induction. *Nature* (2018) 557:57–61. doi: 10.1038/s41586-018-0050-1

49. Zhang X, Shi H, Wu J, Zhang J, Sun L, Chen C, et al. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. *Mol Cell* (2013) 51:226–35. doi: 10.1016/j.molcel.2013.05.022

50. Gao D, Wu J, Wu YT, Du F, Aroch C, Yan N, et al. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. *Science* (2015) 347:aaa2630. doi: 10.1126/science.aaa2630

51. Ishikawa H, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. *Nature* (2009) 461:788–92. doi: 10.1038/nature08476

52. Dobbs N, Burnaevskiy N, Chen D, Gonugunta VK, Alto NM, Yan STING. Activation by translocation of the ER is associated with infection and Autoinflammatory disease. *Cell Host Microbe* (2015) 18:157–68. doi: 10.1016/j.chom.2015.07.001

53. Saitoh T, Fujita N, Hayashi T, Takahara K, Satoh T, Lee H, et al. ATG9a controls dsDNA-driven dynamic translocation of STING and the innate immune response. *Proc Natl Acad Sci USA* (2009) 106:20842–6. doi: 10.1073/pnas.0911267106

54. Ruiz-Mateos J, Lujan-Rodriguez K, Ferrer M, Calvo N, Jimenez-Marin M, et al. STING-dependent autoinflammation and autoimmunity in mice with a targeted disruption of STING. *Nat Immunol* (2016) 17:1057–66. doi: 10.1038/ni.3510

55. Li L, Yin Q, Kuss P, Maliga Z, Millan JL, Wu H, et al. Hydrolysis of 2′,3′-cGAMP. *Nature* (2015) 520:241–7. doi: 10.1038/nature14172

56. Kalamvoki M, Du T, Roizman B. Cells infected with herpes simplex virus 1 (HSV-1) exhibit increased STING-dependent IFN-β production. *Proc Natl Acad Sci USA* (2015) 112:14952–7. doi: 10.1073/pnas.1511628112

57. Gentili M, Kowal J, Tkacova R, Satoh T, Lahaye X, Conrad C, et al. Ribonuclease H2 mutations induce a cGAS/STING-dependent innate immune response. *J Immunol* (2015) 194:1060–7. doi: 10.4049/jimmunol.1402066

58. Jakubiková A, Meyer-Krieglstein K, Pötter M, Zhou Z, Tschopp J, Lanz L, et al. STING-mediated autoinflammatory disease. *Cell Host Microbe* (2018) 19:82–93. doi: 10.1016/j.chom.2018.01.022

59. Watanabe N, Tominaga K, Maruyama K, Omura M, Koyama Y, Ohto M, et al. A requirement for STING in protein synthesis and autoimmunity. *Sci Signal* (2012) 5:ra46. doi: 10.1126/scisignal.2003321

60. Moretti J, Roy S, Bozec D, Martinez J, Chapman JR, Ueberheide B, et al. STING senses microbial viability to orchestrate stress-mediated autophagy of Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. *Cell* (2014) 159:1549–62. doi: 10.1016/j.cell.2014.11.036

61. Snyder HR, Kaiser RH, Warren SL, Heller W. Obsessive-compulsive disorder is associated with broad impairments in executive function: a meta-analysis. *Clin Psychol Sci* (2015) 3:301–30. doi: 10.1177/216770121543210

62. Mackenzie KJ, Carroll P, Lettice L, Tarnaukaite Z, Reddy K, Dix F, et al. Ribonuclease H2 mutations induce a cGAS-STING-dependent innate immune response. *EMBO J* (2016) 35:831–44. doi: 10.15252/embj.201593339

63. Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. *Nature* (2009) 461:788–92. doi: 10.1038/nature08476

64. Dobbs N, Burnaevskiy N, Chen D, Gonugunta VK, Alto NM, Yan STING. Activation by translocation of the ER is associated with infection and Autoinflammatory disease. *Cell Host Microbe* (2015) 18:157–68. doi: 10.1016/j.chom.2015.07.001

65. Saitoh T, Fujita N, Hayashi T, Takahara K, Satoh T, Lee H, et al. ATG9a controls dsDNA-driven dynamic translocation of STING and the innate immune response. *Proc Natl Acad Sci USA* (2009) 106:20842–6. doi: 10.1073/pnas.0911267106

66. Luo WW, Li S, Li C, Liang H, Yang Q, Zhong B, et al. iRhom2 is essential for innate immunity to DNA viruses by mediating trafficking and stability of the adaptor STING. *Nat Immunol* (2016) 17:1057–66. doi: 10.1038/ni.3510

67. Ruiz-Mateos J, Lujan-Rodriguez K, Ferrer M, Calvo N, Jimenez-Marin M, et al. STING-dependent autoinflammation and autoimmunity in mice with a targeted disruption of STING. *Nat Immunol* (2016) 17:1057–66. doi: 10.1038/ni.3510

68. Ruiz-Mateos J, Lujan-Rodriguez K, Ferrer M, Calvo N, Jimenez-Marin M, et al. STING-dependent autoinflammation and autoimmunity in mice with a targeted disruption of STING. *Nat Immunol* (2016) 17:1057–66. doi: 10.1038/ni.3510

69. Ruiz-Mateos J, Lujan-Rodriguez K, Ferrer M, Calvo N, Jimenez-Marin M, et al. STING-dependent autoinflammation and autoimmunity in mice with a targeted disruption of STING. *Nat Immunol* (2016) 17:1057–66. doi: 10.1038/ni.3510
the endoplasmic reticulum. Cell. (2017) 171:809–23.e13. doi: 10.1016/j.cell.2017.09.034
84. Hasan M, Gonugunta VK, Dobbs N, Ali A, Palchik G, Calvinus MA, et al. Chronic innate immune activation of TBK1 suppresses mTORC1 activity and dysregulates cellular metabolism. Proc Natl Acad Sci USA. (2017) 114:746–51. doi: 10.1073/pnas.1611131114
85. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. (2017) 168:960–76. doi: 10.1016/j.cell.2017.02.004
86. Liang Q, Seo GR, Choi YJ, Kwak MJ, Ge J, Rodgers MA, et al. Crosstalk between the cGAS DNA sensor and Beclin-1 autophagy protein shapes innate antimicrobial immune responses. Cell Host Microbe. (2014) 15:228–38. doi: 10.1016/j.chom.2014.01.009
87. Mizushima N. A brief history of autophagy from cell biology to physiology and disease. Nat Cell Biol. (2018) 20:521–7. doi: 10.1038/s41556-018-0092-5
88. Clarke AJ, Simon AK. Autophagy in the renewal, differentiation, and homeostasis of immune cells. Nat Rev Immunol. (2019) 19:170–83. doi: 10.1038/s41577-018-0095-2
89. Liu D, Wu H, Wang C, Li Y, Tian H, Siraj S, et al. STING directly activates priming and activation.
90. Watson RO, Manzanillo PS, Cox JS. Extracellular DNA is protected from NADPH oxidase and LC3-associated phagocytosis by the LCP protein CpsA. Proc Natl Acad Sci USA. (2017) 114:E871–20. doi: 10.1073/pnas.1707792114
91. Watson RO, Mananzano PS, Cox JS. Extracellular DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. Cell. (2012) 150:803–15. doi: 10.1016/j.cell.2012.06.040
92. Senft D, Ronai ZA. UPR, autophagy, and mitochondria crosstalk underlies the ER stress response. Trends Biochem Sci. (2015) 40:141–8. doi: 10.1016/j.tibs.2015.01.002
93. Lan YY, Londono D, Bouley DR, Rooney MS, Hacohen N. Dnase2a deficiency dysregulates cellular metabolism. Proc Natl Acad Sci USA. (2019) 116:29538–43. doi: 10.1073/pnas.1903450116
94. Liu D, Wu H, Wang C, Li Y, Tian H, Siraj S, et al. STING directly activates autophagy to tune the innate immune response. Cell Death Differ. (2019) 26:1735–49. doi: 10.1038/s41418-018-0251-z
95. Koster S, Upadhyay S, Chandra P, Papavinassaudaram K, Yang G, Hassan A, et al. Mycobacterium tuberculosis is protected from NADPH oxidase and LC3-associated phagocytosis by the LCP protein CpsA. Proc Natl Acad Sci USA. (2017) 114:E871–20. doi: 10.1073/pnas.1707792114
96. Gay NJ, Symmons MF, Gangloff M, Bryant CE. Assembly and localization of Toll-like receptor signalling complexes. Nat Rev Immunol. (2014) 14:546–7. doi: 10.1038/nri3713
97. Rongvaux A, Jackson R, Harman CC, Li T, West AP, de Zoete MR, et al. IFI16 mediates NF-kappaB signaling after nuclear DNA damage. Nature. (2018) 71:745–60.e5. doi: 10.1038/s41586-017-0334-4
98. Orzalli MH, Deluca NA, Knipe DM. Nuclear IFI16 induction of IRF-3 signaling during herpesviral infection and degradation of IFI16 by the viral ICP0 protein. Proc Natl Acad Sci USA. (2012) 109:E3008–17. doi: 10.1073/pnas.1211302110
99. Wang Y, Ning X, Gao P, Wu S, Sha M, Lv M, et al. Inflammasome activation during apoptosis. Mol Cell. (2017) 71:745–60.e5. doi: 10.1016/j.molcel.2017.08.034
100. Dunphy G, Flannery SM, Almene JF, Connolly DJ, Paulus C, Jonsson KL, et al. Non-canonical activation of the DNA sensing adaptor STING by ATG and IFI16 mediates NF-kappaB signaling after nuclear DNA damage. Mol Cell. (2018) 71:745–60.e5. doi: 10.1016/j.molcel.2018.07.034
101. Orzalli MH, Deluca NA, Knipe DM. Nuclear IFI16 induction of IRF-3 signaling during herpesviral infection and degradation of IFI16 by the viral ICP0 protein. Proc Natl Acad Sci USA. (2012) 109:E3008–17. doi: 10.1073/pnas.1211302110
102. Jonsson KL, Laustsen A, Krapp C, Thavachelvam K, Hutter D, et al. IFI16 is required for DNA sensing in human macrophages by promoting production and function of cGAMP. Nat Commun. (2017) 8:14391. doi: 10.1038/ncomms14391
103. Almene JF, O’Hare CA, Dunphy G, Haga BA, Nair RJ, Athri A, et al. IFI16 and cGAS cooperate in the activation of STING during DNA sensing in human keratinocytes. Nat Commun. (2017) 8:14392. doi: 10.1038/ncomms14392
104. Orzalli MH, Broekema NM, Diner BA, Hancks DC, Elde NC, Cristea IM, et al. cGAS-mediated stabilization of IFI16 promotes innate signaling during herpes simplex virus infection. Proc Natl Acad Sci. (2015) 112:E1773–81. doi: 10.1073/pnas.1424637112
105. Diner BA, Lum KK, Toetecher JE, Cristea IM. Viral DNA sensors IFI16 and cyclic GMP-AMP synthase possess distinct functions in regulating viral gene expression, immune defenses, and apoptotic responses during herpesvirus infection. mBio. (2017) 8:e01553–16. doi: 10.1128/mBio.01553-16
106. Orzalli MH, DeLuca NA, Knipe DM. Nuclear IFI16 degradation negatively controls Type I interferon production. Cell Rep. (2017) 29:1249–60.e4. doi: 10.1016/j.celrep.2017.09.069
107. Gehrke N, Mertens C, Zillinger T, Wenzel J, Bald T, Zahn S, et al. Oxidative damage of DNA confers resistance to cytosolic nuclearexpression and resistance to an acute DNA virus infection. Immunity. (2015) 43:1148–59. doi: 10.1016/j.immuni.2015.11.015
108. Xu RH, Wong EB, Rubio D, Roscoe F, Ma X, Nair S, et al. Mitochondrial DNA and cell death: outer membrane permeabilisation and beyond. Nat Rev Mol Cell Biol. (2010) 11:621–32. doi: 10.1038/nrm2952
122. Schock SN, Chandra NV, Sun Y, Irie T, Kitagawa Y, Gotob B, et al. Induction of necrototic cell death by viral activation of the RIG-I or STING pathway. Cell Death Differ. (2017) 24:845–25. doi: 10.1038/cdd.2016.153
123. Francica BJ, Ghasemzadeh A, Desblanc A, Theodros D, Sivick KE, Reiner GL, et al. TNFalpha and radioresistant stromal cells are essential for therapeutic efficacy of cyclic dinucleotide STING agonists in nonimmunogenic tumors. Cancer Immunol Res. (2018) 6:422–33. doi: 10.1158/2326-066X.CIR-17-1063
124. Calcinotto A, Kohli J, Zgagato F, Pellegrini L, De Marini M, Alimonti A. Cellular senescence: aging. Cancer Injury Physiol Rev. (2019) 99:1047–78. doi: 10.1152/physrev.00020.2018
125. Krishnamurthy J, Ramsey MR, Ligon KL, Torrice C, Koh A, Bonner-Weir S, et al. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature. (2006) 443:453–7. doi: 10.1038/nature05092
126. Dou Z, Xu C, Donahue H, Shimi T, Pan JA, Zhu J, et al. Autophagy mediates degradation of nuclear lamina. Nature. (2015) 527:105–9. doi: 10.1038/nature15548
127. Lan YY, Heather JM, Eisenhaure T, Garris CS, Lieb D, Raychowdhury R, et al. Downregulation of cytoplasmic DNases is implicated in cytoplasmic DNA accumulation in aged cells and contributes to senescence and inflammation. Aging Cell. (2019) 18:e12901. doi: 10.1111/acel.12901
128. Coppe JP, Patil CK, Rodier F, Sun Y, Irie T, Kitagawa Y, Gotoh B, et al. Induction of extranuclear DNA accumulates in aged cells and contributes to senescence and apoptosis. Cell. (2018) 175:488–501.e22. doi: 10.1016/j.cell.2018.08.062
129. Gluck S, Guey B, Gulen MF, Wolter K, Kang TW, Schmacke NA, et al. Innate immunity activates formation of NEAT1 lncRNA-containing paraspeckles that modulate activation. Nat Med. (2016) 22:861–8. doi: 10.1038/nm.4155
130. Takahashi A, Loo TM, Okada R, Kamachi F, Watanabe Y, Wakita M, et al. Reshaping of the dendritic cell chromatin landscape and interferon pathways during HIV infection. Cell Host Microbe. (2018) 23:366–81.e9. doi: 10.1016/j.chom.2018.01.012
131. Johnson JS, Lucas SY, Amon LM, Skelton S, Nazitto R, Carbonetti S, et al. The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in dendritic cells. Immunity. (2013) 39:1132–42. doi: 10.1016/j.immuni.2013.11.002
132. Lan YY, Heather JM, Eisenhaure T, Garris CS, Lieb D, Raychowdhury R, et al. Extracellular DNA accumulates in aged cells and contributes to senescence and inflammation. Aging Cell. (2019) 18:e12901. doi: 10.1111/acel.12901
133. Yu Q, Katlinskaya YV, Carbone CJ, Zhao B, Katlinski KV, Zheng H, et al. PQBP1 Is a proximal sensor of the cGAS-dependent innate response to DNA-damage-induced type I interferon promotes senescence and inhibits DNA-damage-induced type I interferon. Cell. (2017) 169:387–99.e5. doi: 10.1016/j.molcel.2017.06.020
134. Rasaiyaah J, Tan CP, Fletcher AJ, Price AJ, Blondeau C, Hilditch L, et al. HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature. (2013) 503:402–5. doi: 10.1038/nature12769
135. Dey RJ, Dey B, Zheng Y, Cheung LS, Zhou J, Sayre D, et al. Inhibition of innate immunity protects dormant hematopoietic stem cells from DNA sensor cGAS-mediated degradation of nuclear lamina. Nat Commun. (2018) 9:1249. doi: 10.1038/s41467-018-03555-8
136. Dey R, Dey B, Zheng Y, Cheung LS, Zhou J, Sayre D, et al. Beneficial effects of Yogasanas evades innate immune recognition through specific cofactor recruitment. J Immunol. (2017) 198:2182–90. doi: 10.4049/jimmunol.1600018
137. Weber MM, Lam JL, Dooley CA, Noriea NF, Hansen BT, Hoyt FH, et al. Inhibition of innate immunity protects dormant hematopoietic stem cells from DNA sensor cGAS-mediated degradation of nuclear lamina. Nat Commun. (2018) 9:1249. doi: 10.1038/s41467-018-03555-8
138. Rouhani A, Jelveh F, Godarizadeh S, Khorsandi A, Jouyandeh M, Alimonti A. The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in dendritic cells. Immunity. (2013) 39:1132–42. doi: 10.1016/j.immuni.2013.11.002
139. Rasaiyaah J, Tan CP, Fletcher AJ, Price AJ, Blondeau C, Hilditch L, et al. HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature. (2013) 503:402–5. doi: 10.1038/nature12769
140. Rasaiyaah J, Tan CP, Fletcher AJ, Price AJ, Blondeau C, Hilditch L, et al. HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature. (2013) 503:402–5. doi: 10.1038/nature12769
141. Jena U, Reinders A, Lor C. Cyclic di-GMP: second messenger extraordinare. Nat Rev Microbiol. (2017) 15:271–84. doi: 10.1038/nrmicro.2016.190
142. Cost Pullman MM, Harms K, Chalmers J, Olupot O, Lomax K, et al. A bacterial cyclic di-nucleotide activates the cytosolic surveillance pathway and mediates innate resistance to tuberculosis. Nat Med. (2017) 23:401–6. doi: 10.1038/nm.4318
143. Chidambaran M, Kaper JB, Shah SH, et al. Group B Streptococcus triggers a cGAS-independent STING pathway to initiate host protection that involves guanylate-binding proteins and inflammasome activation. J Immunol. (2018) 200:667–22. doi: 10.4049/jimmunol.1700725
144. Rajani S, Archania R, Indla YR, Rajesh P. Beneficial effects of Yogasanas and Pranayama in the limiting cognitive decline in Type 2 Diabetes. Nat J Physiol Pharm Pharmacol. (2017) 7:232–5. doi: 10.5455/njpp.2017.7.082550892016
145. Andrade WA, Firon A, Schmidt T, Hormung V, Fitzgerald KA, Kurt-Jones EA, et al. Group B Streptococcus degrades cyclic-di-AMP to modulate STING-dependent Type I interferon production. Cell Host Microbe. (2016) 20:49–59. doi: 10.1016/j.chom.2016.06.003
146. Weber MM, Lam JL, Dooley CA, Noriea NF, Hansen BT, Hoyt FH, et al. Absence of specific Chlamydia trachomatis inclusion membrane proteins triggers premature inclusion membrane lysis and host cell death. Cell Rep. (2017) 19:1406–17. doi: 10.1016/j.celrep.2017.04.058
147. Weber MM, Lam JL, Dooley CA, Noriea NF, Hansen BT, Hoyt FH, et al. Absence of specific Chlamydia trachomatis inclusion membrane proteins triggers premature inclusion membrane lysis and host cell death. Cell Rep. (2017) 19:1406–17. doi: 10.1016/j.celrep.2017.04.058
148. Rajani S, Archania R, Indla YR, Rajesh P. Beneficial effects of Yogasanas and Pranayama in the limiting cognitive decline in Type 2 Diabetes. Nat J Physiol Pharm Pharmacol. (2017) 7:232–5. doi: 10.5455/njpp.2017.7.082550892016
149. Andrade WA, Firon A, Schmidt T, Hormung V, Fitzgerald KA, Kurt-Jones EA, et al. Group B Streptococcus degrades cyclic-di-AMP to modulate STING-dependent Type I interferon production. Cell Host Microbe. (2016) 20:49–59. doi: 10.1016/j.chom.2016.06.003
150. Rajani S, Archania R, Indla YR, Rajesh P. Beneficial effects of Yogasanas and Pranayama in the limiting cognitive decline in Type 2 Diabetes. Nat J Physiol Pharm Pharmacol. (2017) 7:232–5. doi: 10.5455/njpp.2017.7.082550892016
151. Rajani S, Archania R, Indla YR, Rajesh P. Beneficial effects of Yogasanas and Pranayama in the limiting cognitive decline in Type 2 Diabetes. Nat J Physiol Pharm Pharmacol. (2017) 7:232–5. doi: 10.5455/njpp.2017.7.082550892016
161. Wang et al. cGAS-STING Pathway

162. Nandakumar R, Tschismarov R, Meissner F, Prabakaran T, Krishnanprasad A, Farahani E, et al. Intracellular bacteria engage a STING-TBK1-MVB12b pathway to enable paracrine cGAS-STING signalling. Nat Microbiol. (2019) 4:701–13. doi: 10.1038/s41564-019-0367-z

163. Archer KA, Durack J, Portnoy DA. STING-dependent type I IFN production inhibits cell-mediated immunity to Listeria monocytogenes. PLoS Pathog. (2014) 10:e1003861. doi: 10.1371/journal.ppat.1003861

164. Majumdar T, Chattopadhyay S, Ozhegov E, Dhar J, Goswami R, Sen GC, et al. Induction of interferon-stimulated genes by IRF3 promotes replication of Toxoplasma gondii. PLoS Pathog. (2015) 11:e1004779. doi: 10.1371/journal.ppat.1004779

165. Situssella X, Ofrir-Binir Y, Pimentel MA, Cheng L, Abou Karam P, Sampaio NG, et al. Malaria parasite DNA-harbouring vesicles activate cytosolic immune sensors. Nat Commun. (2017) 8:1985. doi: 10.1038/s41467-017-02083-1

166. Muskardin TLW, Niewold TB. Type I interferon in rheumatic diseases. Nat Rev Rheumatol. (2018) 14:214–28. doi: 10.1038/nrrheum.2018.31

167. Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg MC, et al. Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling. Eur J Immunol. (2018) 48:1615–21. doi: 10.1002/eji.201546113

168. Banchereau R, Hong S, Cantarel B, Baldwin N, Baisch J, Edens M, et al. Activation of the STING-IRF3 pathway promotes hepatic inflammation and fibrosis in mice. J Exp Med. (2017) 214:3279–92. doi: 10.1084/jem.201611351

169. Bouis C, Fox M, Tewary P, Steinhagen A, Ellerkmann RK, Klinman D, et al. STING-dependent sensing of self-DNA drives silica-induced lung epithelial injury. Cell Metab. (2018) 22:146–53. doi: 10.1016/j.cmet.2019.09.003

170. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. (2001) 294:1540–3. doi: 10.1126/science.1064890

171. Lood C, Blanco LP, Purmalek MM, Carmona-Rivera C, De Ravin SS, Smith CK, et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med. (2016) 22:146–53. doi: 10.1038/nm.4027

172. Garcia-Romo GS, Caelli S, Vega B, Connolly J, Allantaz F, Xu Z, et al. Neutrophil neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. (2011) 3:73ra20. doi: 10.1126/scitranslmed.3001201

173. Guo S, Saito Y, Ouyang H, Wang C, Connolly J, Allantaz F, et al. Cytosolic DNA sensing promotes macrophage transformation and governs myocardial ischemic injury. Circulation. (2018) 137:2613–34. doi: 10.1161/CIRCULATIONAHA.117.031046

174. King KR, Aguirre AD, Ye YX, Sun Y, Roh JD, Ng RP Jr, et al. IRF3 and type I interferons fuel a fatal response to myocardial infarction. Nat Med. (2017) 23:1481–7. doi: 10.1038/nm.4428

175. Qiao JT, Cui C, Qng L, Wang LS, He TY, Yan F, et al. Activation of the STING-IRF3 pathway promotes hepatocyte inflammation, apoptosis and induces metabolic disorders in nonalcoholic fatty liver disease. Metabolism. (2018) 81:13–24. doi: 10.1016/j.metabol.2017.09.010

176. Luo X, Li H, Ma L, Zhou J, Guo X, Woo SL, et al. Expression of STING is increased in liver tissues from patients with NAFLD and promotes macrophage-mediated hepatic inflammation and fibrosis in mice. Gastroenterology. (2018) 155:1971–84.e4. doi: 10.1053/j.gastro.2018.09.010

177. Yu Y, Liu Y, An W, Song J, Zhang Y, Zhao X. STING-mediated inflammation in Kupfer cells contributes to progression of nonalcoholic steatohepatitis. J Clin Investig. (2019) 129:546–55. doi: 10.1172/JCI121842

178. Cho CS, Park HW, Ho A, Semple IA, Kim B, Jang I, et al. Lipotoxicity induces hepatic protein inclusions through TANK binding kinase 1-mediated p62/sequestosome 1 phosphorylation. Hepatology. (2018) 68:1331–46. doi: 10.1002/hep.29742

179. Mao Y, Luo W, Zhang L, Wu W, Yuan L, Xu H, et al. STING-IRF3 triggers endothelial inflammation in response to free fatty acid-induced mitochondrial damage in diet-induced obesity. Arterioscler Thromb Vasc Biol. (2017) 37:920–9. doi: 10.1161/ATVBAHA.117.309017

180. Witcher KG, Eiferman DS, Godbout JP. Priming the inflammatory pump of the CNS after traumatic brain injury. Trends Neurosci. (2015) 38:609–20. doi: 10.1016/j.tins.2015.08.002

181. Abdullah A, Zhang M, Frugier T, Bedoui S, Taylor JM, Crack PJ. STING-mediated mitochondrial damage in diet-induced obesity. Cell Metab. (2016) 23:1481–7. doi: 10.1016/j.cmet.2016.05.057

182. Kato Y, Park J, Takamatsu H, Konaka H, Aoki W, Aburaya S, et al. Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus. Ann Rheum Dis. (2018) 77:1507–15. doi: 10.1136/annrheumdis-2018-219298

183. Crow YJ, Manel N. Aicardi-goutieres syndrome and the type I interferonopathies. Nat Rev Immunol. (2015) 15:429–40. doi: 10.1038/nri3850

184. Cho CS, Park HW, Ho A, Semple IA, Kim B, Jang I, et al. Lipotoxicity induces hepatic protein inclusions through TANK binding kinase 1-mediated p62/sequestosome 1 phosphorylation. Hepatology. (2018) 68:1331–46. doi: 10.1002/hep.29742

185. Benmerzoug S, Rose S, Bounab B, Gossot D, Dunaeu L, Chenuet P, et al. STING-dependent sensing of self-DNA drives silica-induced lung inflammation. Nat Commun. (2018) 9:5226. doi: 10.1038/s41467-018-07425-1

186. Chung KW, Dhillon P, Huang S, Sheng X, Shrestha R, Qiu C, et al. Mitochondrial damage and activation of the STING pathway lead to renal inflammation and fibrosis. Cell Metab. (2019) 30:784–99.e5. doi: 10.1016/j.cmet.2019.08.003

187. Maekawa H, Inoue T, Ouchi H, Jao TM, Inoue R, Nishi H, et al. Interleukin-1beta induces mtDNA release to activate innate immune signaling via cGAS-STING. Mol Cell. (2019) 74:801–15.e6. doi: 10.1016/j.molcel.2019.02.038

188. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. (2001) 294:1540–3. doi: 10.1126/science.1064890

189. Lood C, Blanco LP, Purmalek MM, Carmona-Rivera C, De Ravin SS, Smith CK, et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med. (2016) 22:146–53. doi: 10.1038/nm.4027

190. Garcia-Romo GS, Caelli S, Vega B, Connolly J, Allantaz F, Xu Z, et al. Neutrophil neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. (2011) 3:73ra20. doi: 10.1126/scitranslmed.3001201

191. Nazmi A, Field RH, Griffin EW, Haugh O, Hennessy E, Cox D, et al. Chronic neurodegeneration induces type I interferon synthesis via STING,
shaping microbial phenotype and accelerating disease progression. *Glia* (2019) 67:1254–76. doi: 10.1002/glia.23592

199. Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson’s disease. *Neuron*. (2015) 85:257–73. doi: 10.1016/j.neuron.2014.12.007

200. Sliter DA, Martinez J, Hao L, Chen X, Sun N, Fischer TD, et al. Parkin and PINK1 mitigate STING-induced inflammation. *Nature*. (2018) 561:258–62. doi: 10.1038/s41586-018-0448-9

201. McKinNON PN, ATm and the molecular pathology of ataxia telangiectasia. *Annu Rev Physiol*. (2012) 73:301–21. doi: 10.1146/annurev-physiol-061911-113209

202. Ammann AJ, Hong R. Autoimmune phenomena in ataxia telangiectasia. *Pediatr*. (1971) 78:821–6. doi: 10.1002/sim.8471780353-0

203. Dib B, Lin H, MaidaNA DE, Tian B, Miller JB, Bouzika P, et al. Mitochondrial DNA has a pro-inflammatory role in AMD. *Biochim Biophys Acta*. (2015) 1853(11 Pt A):2897–906. doi: 10.1016/j.bbamcr.2015.08.012

204. Kerur N, Fukuda S, Banerjee D, Kim Y, Fu D, Apicella I, et al. cGAS drives dendritic cell death in cancer and infectious disease. *Nat Rev Immunol*. (2017) 17:97–111. doi: 10.1038/nri.2016.107

205. Okhuri T, Ghosh A, Kosaka A, Zhu J, Ikeura M, David M, et al. STING contributes to antiglial immunity via triggering type I IFN signals in the tumor microenvironment. *Cancer Res*. (2014) 74:1199–208. doi: 10.1158/2326-6266.CIR-13-0186

206. Yan H, Lee WS, Kong SJ, Kim CG, Kim JH, Chang SK, et al. STING signaling promotes T lymphocytes. *J Immunol*. (2018) 201:2641–53. doi: 10.4049/jimmunol.1701405

207. Tang CH, Zundell JA, Ranatunga S, Lin C, Nefedova Y, Del Valle JR, et al. B cell-Intrinsic STING signaling triggers cell activation, synergizes with B cell receptor signals, and promotes antibody responses. *J Immunol*. (2018) 201:2641–53. doi: 10.4049/jimmunol.1701405

208. Zhai Q, Wei Y, Pandol SJ, Li L, Hatzétzion A. STING signaling promotes immunosuppression in experimental acute pancreatitis. *Gastroenterology*. (2018) 154:1822–35.e2. doi: 10.1053/j.gastro.2018.01.065

209. Zhao Q, Manohar M, Wei Y, Pandol SJ, Hatzétzion A. STING signalling protects against chronic pancreatitis by modulating Th17 response. *Gut*. (2019) 68:1827–37. doi: 10.1136/gutjnl-2018-317098
systemic antitumor immunity. *Cancer Immunol Res.* (2017) 5:676–84. doi: 10.1158/2326-6066.CIR-17-0049

239. Zhang CX, Ye SB, Ni JJ, Cai TT, Liu YN, Huang DJ, et al. STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion. *Cell Death Differ.* (2019) 26:2314–28. doi: 10.1038/s41418-019-0302-0

240. Santana Carrero RM, Beceren-Braun F, Rivas SC, Hegde SM, Gangadharan A, Ploet D, et al. IL-15 is a component of the inflammatory milieu in the tumor microenvironment promoting antitumor immunity. *Proc Natl Acad Sci USA.* (2019) 116:599–608. doi: 10.1073/pnas.181462116

241. Konno H, Yamauchi S, Berglund A, Putney RM, Mule JJ, Barber GN. Downregulation of membrane trafficking proteins and lactate conditioning determine loss of dendritic cell function in lung cancer. *Cancer Res.* (2018) 78:1685–99. doi: 10.1158/0008-5472.CAN-17-1307

242. Wu S, Zhang Q, Zhang F, Meng F, Li S, Zhou R, et al. HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity. *Nat Cell Biol.* (2021) 21:1027–40. doi: 10.1038/s41556-019-0352-z

243. Caronni N, Simoncello F, Stafetta F, Guarnaccia C, Ruiz-Moreno JS, Opitz MA, et al. Magnitude of therapeutic STING activation determines CD8(+) T Cell-mediated anti-tumor immunity. *Cell Rep.* (2020) 25:3074–85.e5. doi: 10.1016/j.celrep.2018.11.047

244. Chen Q, Boire A, Jin X, Valiente M, Er EE, Lopez-Soto A, et al. DNA damage sensing pathway. *Nat Struct Mol Biol* (2017) 24(12):1124–31. doi: 10.1038/nsmb.3498

245. Carozzi N, Simoncello F, Stafetta F, Guarnaccia C, Ruiz-Moreno JS, Opitz MA, et al. Design of amidobenzimidazole STING receptor agonists with systemic antitumor immunity. *Oncoimmunology* (2017) 6:e1346765. doi: 10.1080/2162402X.2017.1346765

246. Chabbanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, et al. PARP inhibition enhances tumor-cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. *J Clin Invest.* (2019) 129:1211–28. doi: 10.1172/JCI123319

247. Cantelidou C, Sonzogni O, De Oliveria Taveira M, Mehta AK, Kothari A, Wang D, et al. PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. *Cancer Discov.* (2019) 9:722–37. doi: 10.1158/2159-8290.CD-18-1218

248. Baird JR, Friedman D, Cottam B, Dubensky TW Jr., Kanne DB, Bambina S, et al. Radiotherapy combined with novel STING-targeting Oligonucleotides results in regression of established tumors. *Cancer Immunol Res.* (2017) 5:1709–17. doi: 10.1158/2326-6066.CIR-16-0284

249. Haneke E, Schlaeger TM, Annapragada A, Marquez-Rodriguez P, Choi H, et al. STING ligand c-di-GMP improves cancer vaccination against locally advanced non-small-cell lung cancer. *J Clin Oncol* (2019) 27:3564–73. doi: 10.1200/JCO.18.02828

250. Wang M, Sooreshjahi MA, Mitek C, Opoika-Temeng C, Sintim HO, Suramin potentiates cGAS-STING pathway activation in THP1 cells to modulate IFN-beta levels. *Future Med Chem.* (2018) 10:1301–17. doi: 10.4155/fmc-2017-0322

251. Vincent J, Adura C, Gao P, Liu X, Pu Y, Ceron K, Deng L, Kline J, Frazier WA, et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. *Nat Med.* (2015) 21:1209–15. doi: 10.1038/nm.3931

252. Demaria O, De Gassart A, Coso S, Gestermann N, Di Domizio J, Flatz L, et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. *Proc Natl Acad Sci USA.* (2015) 112:15408–13. doi: 10.1073/pnas.1512832112

253. Sanjuan R, Barredo M, Hernandez-Ramos R, Martinez-Fresneda M, Del Pozo V, et al. STING agonist given with OX40 receptor and PD-1: L1 modulators primes immunity and reduces tumor growth in tolerized mice. *Cancer Immunol Res.* (2017) 5:488–79. doi: 10.1158/2326-6066.CIR-16-0284

254. Liu X, Pu Y, Ceron K, Deng L, Kline J, Frazier WA, et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. *Nat Med.* (2015) 21:1209–15. doi: 10.1038/nm.3931

255. Foote JB, Kok M, Leatherman JM, Armstrong TD, Marcinkowski BC, Ojavo LS, et al. A STING agonist given with OX40 receptor and PD-L1 modulators primes immunity and reduces tumor growth in tolerized mice. *Cancer Immunol Res.* (2017) 5:488–79. doi: 10.1158/2326-6066.CIR-16-0284

256. Foote JB, Kok M, Leatherman JM, Armstrong TD, Marcinkowski BC, Ojavo LS, et al. A STING agonist given with OX40 receptor and PD-L1 modulators primes immunity and reduces tumor growth in tolerized mice. *Cancer Immunol Res.* (2017) 5:488–79. doi: 10.1158/2326-6066.CIR-16-0284

257. Liu X, Pu Y, Ceron K, Deng L, Kline J, Frazier WA, et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. *Nat Med.* (2015) 21:1209–15. doi: 10.1038/nm.3931
274. Dai J, Huang YJ, He X, Zhao M, Wang X, Liu ZS, et al. Acetylation Blocks cGAS Activity and Inhibits Self-DNA-Induced Autointimunity. *Cell*. (2019) 176:1447–60.e14. doi: 10.1016/j.cell.2019.01.016

275. Li S, Hong Z, Wang Z, Li F, Mei J, Huang L, et al. The cyclopeptide astin C specifically inhibits the innate immune CDN sensor STING. *Cell Rep*. (2018) 25:3405–21.e7. doi: 10.1016/j.celrep.2018.11.097

276. Haag SM, Gulen MF, Reymond L, Gibelain A, Abrami L, Decout A, et al. Targeting STING with covalent small-molecule inhibitors. *Nature*. (2018) 559:269–73. doi: 10.1038/s41586-018-0288-7

277. Seo GJ, Kim C, Shin WJ, Sklan EH, Eoh H, Jung JU. TRIM56-mediated monoubiquitination of cGAS for cytosolic DNA sensing. *Nat Commun*. (2018) 9:1631. doi: 10.1038/s41467-018-02936-3

278. Chen Y, Wang L, Jin J, Luan Y, Chen C, Li Y, et al. p38 inhibition preferentially promotes DNA and RNA virus-induced production of type I interferon by recruiting GSK3beta to TBK1. *Immunity*. (2010) 33:765–76. doi: 10.1016/j.immuni.2010.10.013

279. Wang Q, Huang L, Hong Z, Lv Z, Mao Z, Tang Y, et al. The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA. *Immunity*. (2010) 33:757–6. doi: 10.1016/j.immuni.2010.10.013

280. Wang Q, Liu X, Cui Y, Tang Y, Chen W, Li S, et al. The E3 ubiquitin ligase AMFR and STING activation. *Cell* (2017) 168:1447–60.e14. doi: 10.1016/j.cell.2019.01.016

281. Dai J, Huang YJ, He X, Zhao M, Wang X, Liu ZS, et al. Acetylation Blocks cGAS Activity and Inhibits Self-DNA-Induced Autointimunity. *Cell*. (2019) 176:1447–60.e14. doi: 10.1016/j.cell.2019.01.016

282. Liu TT, Yang Q, Li M, Zhong B, Ran Y, Liu LL, et al. Lsm14A plays a critical role in antiviral immune responses by regulating MITA in a cell-specific manner. *Immunity*. (2016) 46:3101–10. doi: 10.1016/j.immuni.2016.09.008

283. Xing J, Zhang A, Zhang H, Wang J, Li XC, Zeng MS, et al. TRIM29 promotes DNA virus infections by inhibiting innate immune response. *Nat Commun*. (2017) 8:945. doi: 10.1038/s41467-017-00101-w

284. Li Z, Liu G, Sun L, Teng Y, Guo X, Jia J, et al. PPM1A regulates antiviral responses by deubiquitinating STING. *Nat Immunol*. (2017) 18:1553. doi: 10.1038/natura15534

285. Ghosh A, Shao L, Sampath P, Zhao B, Patel NV, Zhu J, et al. Oligoadenylate-synthetase-family protein OASL inhibits activity of the DNA sensor cGAS during DNA virus infection to limit interferon production. *Immunity*. (2019) 50:51–63.e5. doi: 10.1016/j.immuni.2018.12.013

286. Lon, KK, Song B, Federspiel JD, Diner BA, Howard T, Cristea IM. Interactome and proteome dynamics uncover immune modulatory associations of the pathogen sensing factor cGAS. *Cell Syst*. (2018) 7:627–42.e6. doi: 10.1016/j.cels.2018.10.010

287. Srikanth S, Woo JS, Wu B, El-Sherbiny YM, Leung J, Chupradit K, et al. The Ca(2+)-sensor STIM1 regulates the type I interferon response by targeting STING. *Cell* (2019) 177:627–42.e6. doi: 10.1016/j.cell.2018.10.010

288. Li Z, Liu G, Sun L, Teng Y, Guo X, Jia J, et al. The Ca(2+)-sensor STIM1 regulates the type I interferon response by retaining the signaling adaptor STING at the endoplasmic reticulum. *Nat Immunol*. (2019) 20:152–62. doi: 10.1038/s41590-018-0262-4

289. Hansen AL, Buchan GJ, Ruhl M, Mukai K, Salvatore SR, Ogawa E, et al. Nitro-fatty acids are formed in response to virus infection and are potent inhibitors of STING palmitoylation and signaling. *Proc Natl Acad Sci USA*. (2018) 115:E7768–75. doi: 10.1073/pnas.1806239115

290. Zhang L, Mo J, Swanson KV, Wen H, Petrucci A, Gregory SM, et al. NLR3, a member of the NLR family of proteins, is a negative regulator of innate immune signaling induced by the DNA sensor STING. *Immunity*. (2014) 40:329–41. doi: 10.1016/j.immuni.2014.01.010

291. Li Z, Liu G, Sun L, Teng Y, Guo X, Jia J, et al. PPM1A regulates antiviral signaling by antagonizing TBK1-mediated STING phosphorylation and aggregation. *Plos Pathog*. (2015) 11:e1004783. doi: 10.1371/journal.ppat.1004783

292. Xia T, Yi XM, Wu X, Shang J, Shu HB. PTPN11-mediated dephosphorylation of MITA/STING promotes its 20S proteasomal degradation and attenuates innate antiviral response. *Proc Natl Acad Sci USA*. (2019) 116:20063–9. doi: 10.1073/pnas.1906431116
310. Guo H, Konig R, Deng M, Riess M, Mo J, Zhang L, et al. NLRX1 sequesters STING to negatively regulate the interferon response, thereby facilitating the replication of HIV-1 and DNA viruses. *Cell Host Microbe*. (2016) 19:515–28. doi: 10.1016/j.chom.2016.03.001

311. Feng H, Lenarcic EM, Yamane D, Wauthier E, Mo J, Guo H, et al. NLRX1 promotes immediate IRE1-directed antiviral responses by limiting dsRNA-activated translational inhibition mediated by PKR. *Nat Immunol*. (2017) 18:1299–309. doi: 10.1038/nri.3853

312. Tan YS, Sansanaphongpricha K, Xie Y, Donnelly CR, Luo X, Heath BR, et al. Mitigating SOX2-potentiated immune escape of head and neck squamous cell carcinoma with a STING-inducing nanoscaffold vaccine. *Clin Cancer Res*. (2018) 24:4242–55. doi: 10.1158/1078-0432.CCR-17-2807

313. Wu MZ, Cheng WC, Chen SF, Nieh S, O’Connor C, Liu CL, et al. miR-25/93 promotes immediate IFN-dependent innate immunity. *Cell Death Dis*. (2018) 9:125. doi: 10.1038/s41467-018-05861-7

314. Olagnier D, Brandtoft AM, Gunderstofte C, Villadsen NL, Krapp C, Thielke Tegument Protein VP22 abrogates cGAS/STING-mediated antiviral innate immunity. *J Virol*. (2018) 92:e00841-18. doi: 10.1128/JVI.00841-18

315. Zhang J, Zhao J, Xu S, Li J, He S, Zeng Y, et al. Species-specific deactivation of cGAS by herpes simplex virus UL37 protein facilitates viral replication. *Cell Host Microbe*. (2018) 24:234–48.e5. doi: 10.1016/j.chom.2018.07.004

316. Deschamps T, Kalamvoki M. Evasion of the STING DNA-sensing pathway by VP11/12 of herpes simplex virus 1. *J Virol*. (2017) 91:e02414-16. doi: 10.1128/JVI.02414-16

317. Huang J, You H, Su C, Li Y, Chen S, Zheng C. Herpes simplex virus 1 Tegument Protein VP22 abrogates cGAS-STING-mediated antiviral innate immunity. *J Virol*. (2018) 92:e00841-18. doi: 10.1128/JVI.00841-18

318. Huang ZF, Zou HM, Liao BW, Zhang HY, Yang Y, Fu YZ, et al. Human Cytomegalovirus Protein UL31 Inhibits DNA Sensing of cGAS to Mediate Immune Evasion. *Cell Host Microbe*. (2018) 24(1):69–80.e4. doi: 10.1016/j.chom.2018.05.007

319. Biotatti M, Dell’Oste V, Pautasso S, Gugliesi F, von Einem J, Karrp C, et al. Human Cytomegalovirus Tegument Protein pp65 (pUL83) dampens Type I interferon production by inactivating the DNA sensor cGAS without affecting STING. *J Virol*. (2018) 92:e01774-17. doi: 10.1128/JVI.01774-17

320. Kumari P, Saha I, Narayanan A, Narayanan S, Takaoka A, Kumar NS, et al. Essential role of HCMV deubiquitinase in promoting oncosogenesis by targeting anti-viral innate immune signaling pathways. *Cell Death Dis*. (2017) 8:e3078. doi: 10.1038/cddis.2017.461

321. Fu YZ, Su S, Gao YQ, Wang PP, Huang ZF, Hu MM, et al. Human Cytomegalovirus Tegument Protein UL82 inhibits STING-mediated signaling to evade antiviral innate immunity. *Cell Host Microbe*. (2017) 21:231–43. doi: 10.1016/j.chom.2017.01.001

322. Stemple M, Chan B, Juranic Lisnic V, Krmptocic A, Hartung J, Paludan SR, et al. The herpesviral antagonist m152 reveals differential activation of STING-dependent IRF and NF-kappaB signaling and STING’s dual role during MCMV infection. *EMBO J*. (2019) 38:e100983. doi: 10.15252/embj.2018100983

323. Choi HJ, Park A, Kang S, Lee E, Lee TA, Ra EA, et al. Human cytomegalovirus-encoded US9 targets MAVS and STING signaling to evade type I interferon immune responses. *Nat Commun*. (2018) 9:125. doi: 10.1038/s41467-017-02624-8

324. Wu JJ, Li W, Shao Y, Avey D, Fu B, Gillen J, et al. Inhibition of cGAS DNA Sensing by a Herpesvirus Virion protein. *Cell Host Microbe*. (2015) 18:333–44. doi: 10.1016/j.chom.2015.07.015

325. Zhang G, Chan B, Samarina N, Abere B, Weidner-Glunde M, Buch A, et al. Cytoplasmic isoforms of Kaposi sarcoma herpesvirus LANa recruit and antagonize the innate immune DNA sensor cGAS. *Proc Natl Acad Sci USA*. (2016) 113:E1034–43. doi: 10.1073/pnas.1516811112

326. Ma Z, Jacobs SR, West JA, Stopford C, Zhang Z, Davis Z, et al. Modulation of the cGAS-STING DNA sensing pathway by gammaherpesviruses. *Proc Natl Acad Sci USA*. (2015) 112:E4306–15. doi: 10.1073/pnas.1503831112

327. Chen X, Yang X, Zheng Y, Yang Y, Xing Y, Chen Z. SARS coronavirus papain-like protease inhibits the type I interferon signaling pathway through interaction with the STING-TRAF3-TBK1 complex. *Protein Cell*. (2014) 5:369–81. doi: 10.1007/s13238-014-0026-3

328. Meade N, Furey C, Li H, Verma R, Chai Q, Rolins MG, et al. Poxxviruses evade cytosolic sensing through disruption of an mTORC1-mTORC2 regulatory circuit. *Cell*. (2018) 174:1143–57.e17. doi: 10.1016/j.cell.2018.06.053

329. Eaglesham JB, Pan Y, Kupper TS, Kranzusch PJ. Viral and metazoan poxins are cGAMP-specific nucleases that restrict cGAS-STING signaling. *Nature*. (2019) 566:259–63. doi: 10.1038/s41586-019-0928-6

330. Zheng Y, Liu Q, Wu Y, Ma L, Zhang Z, Liu T, et al. Zika virus everts inflammation to evade antiviral response by cleaving cGAS via NS1-caspase-1 axis. *EMBO J*. (2018) 37:e99347. doi: 10.15252/embj.201899347

331. Aguirre S, Maestre AM, Pagni S, Patel T, Savage T, Gutman D, et al. DENV inhibits type I IFN production in infected cells by cleaving human STING. *PLoS Pathog*. (2012) 8:e1002934. doi: 10.1371/journal.ppat.1002934

332. Aguirre S, Luthra P, Sanchez-Aparicio MT, Maestre AM, Patel J, Lamotte F, et al. Dengue virus NS2B protein targets cGAS for degradation and prevents mitochondrial DNA sensing during infection. *Nat Microbiol*. (2017) 2:17037. doi: 10.1038/nmicrobiol.2017.37

333. Lau L, Gray EE, Brunette RL, Stetson DB. DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway. *Science*. (2015) 350:658–71. doi: 10.1126/science.aab3291

334. Holm CK, Rahbek SH, Gad HH, Bak RO, Jakobsen MR, Jiang Z, et al. Influenza A virus targets a cGAS-independent STING pathway that controls enveloped RNA viruses. *Nat Commun*. (2016) 7:10680. doi: 10.1038/ncomms10680

335. Ding Q, Cao X, Lu J, Huang B, Liu YJ, Kato N, et al. Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity. *J Hepatol*. (2013) 59:52–8. doi: 10.1016/j.jhep.2013.03.019

336. Nitta S, Sakamoto N, Nakagawa M, Kakinuma S, Mishima K, Kusano-Kitazume A, et al. Hepatitis B virus protein antagonizes the innate immune DNA sensor cGAS. *Nat Commun*. (2015) 6:7180. doi: 10.1038/ncomms10680

337. Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Wan, Jiang and Hao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.